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ABSTRACT
NON-REDUNDANT AND CRITICAL ROLES FOR LEUKOTRIENE B4 RECEPTORS,
BLTl AND BLT2, IN MOUSE MODELS OF INFLAMMATORY ARTHRITIS

Steven Mathis
April 4, 2007
Inflammation is now recognized as an important factor in several age-related
diseases such as arthritis, atherosclerosis, multiple sclerosis and diabetes. In each case,
sub-clinical chronic inflammation occurs over years and leads to progressive destruction
of the tissue until the symptoms become clinically apparent. Eicosanoids such as
prostaglandins and leukotrienes play an important role in inflammation. Among these,
leukotriene B4 (L TB 4) has had a long history of being associated with numerous
inflammatory diseases. A high affinity receptor for LTB 4, LTB4 receptor 1 (BL Tl) has
been well-characterized in human and murine tissues. While the molecular mechanisms
remain unclear, its importance in diverse inflammatory diseases was demonstrated in
mice lacking BL Tl. More recently, a second highly conserved low affinity LTB4
receptor, LTB4 receptor 2 (BL T2) was identified, but its functional significance remains
completely unknown. Both BLTI and BLT2 are seven-transmembrane G protein coupled
receptors transducing signals through heterotrimeric G-proteins.
Chapter II of this thesis describes the generation and characterization of
monoclonal antibodies to BLTl. Immunization of BL Tl-deficient mice with 300.19, a
murine pre-B cell line expressing high levels of either human or murine BLTI allowed
isolation of highly species specific anti-BLTI antibodies. Using an approach involving a

series of human/murine BLTI chimeric receptors the monoclonal antibody binding sites
were mapped to extracellular 100p-2. Extensive characterization of BLTI in murine

v

pnmary cells revealed high levels of BL Tl in neutrophils and eosinophils and a
previously unsuspected regulation of BL Tl in macrophages. While bone marrow derived
macrophages expressed high levels of BLTI its expression in peripheral tissue
macrophages was significantly reduced suggesting a potential novel mechanism, and a
role for BL Tl in inflammation-induced egress of bone marrow derived cells. The
antibodies also allowed demonstration of normal BLTI expression in the recently
generated BL T2 deficient mice. Future studies could explore the therapeutic potential of
these antibodies.
In Chapter III, we investigated the role of BLTl and BLT2 in inflammatory
arthritis in mouse models. Collagen induced arthritis (CIA) is a model where mice are
immunized with chicken collagen type II in complete freund's adjuvant and leads to a
polyarthritis in the distal joints. BLTl deficient mice on the DBA!l background were
completely protected from the development of CIA which confirms the prevIOUS
observations with BLTI antagonists and BLTl deficient mIce on the C57B1I6
background.
Arthritis was also induced by transfer ofKlBxN serum to naIve mice. KlBxN is a
T cell receptor transgenic mouse (KRN) crossed with a NOD mouse.

These mice

spontaneously develop arthritis due to auto-antibody production against glucose-6phosphate isomerase, a ubiquitous enzyme. In this model, we report for the first time that
BL T2

deficient

mice

are

completely

protected

from

inflammatory

arthritis.

Histopathologic examination revealed a massive inflammatory cell influx in wild-type
mice that was completely absent in BL T2 deficient mice. Further analysis of these mice

using bone marrow transplantation studies demonstrated development

VI

of arthritis requires

BL T2 expression on bone marrow-derived cells. Wild-type mice which received bone
marrow from BLT2 -1- mice showed little sign of disease on histological analysis, while

BLT2-1- mice receiving wild-type bone marrow showed intense inflammation leading to
severe destruction in cartilage and bone. When BLTI/BLT2 double deficient mice were
transplanted with a mixture of BL Tl deficient and BLT2 deficient bone marrow, a gain
of clinical disease was observed. All these data demonstrate that BLT2 has a critical role
in arthritis and it is non-redundant with the role played by BLTI. Further study is needed
to determine the function of BLT2 and in which cell types it is important.
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CHAPTER I

GENERAL INTRODUCTION

INTRODUCTION
A. Biosynthesis of Leukotrienes

Leukotrienes have been linked to inflammation for decades. The importance of
these mediators was realized in 1980 when the slow-reacting substance of anaphylaxis
was discovered to consist predominantly of LTC 4 with a lower content of LTD4 and LTE4
(1). In the same year, it was established that LTB4 serves as a potent chemoattractant for

neutrophils (2). LTB4 is a derivative of arachidonic acid (AA), found in cell membranes.
Upon activation of a cell, cytosolic phospholipase A2 releases AA from the membrane
where it is acted upon by 5-lipoxygenase (5-LO) in concert with 5-lipoxygenase
activating protein (FLAP) to produce leukotriene A4 (LTA4).

LTA4 can either be

converted to leukotriene C4 through the addition of glutathione (aSH) by LTC 4 synthase,
or alternatively, can be converted to LTB4 by LTA4 hydrolase (LTA4H). A scheme of
leukotriene biosynthesis is shown in Figure 1. LT~ is exclusively made by leukocytes
and is exported to endothelial cells to be converted into LTB4 or LTC 4 where LTA4
hydrolase and LTC 4 synthase are present, which is an interesting phenomenon termed
transcellular synthesis(3).

1

Figure 1: The Arachidonic Acid Pathway. Arachidonic acid is synthesized from
phospholipids by phospholipase A2 (PLA2). The conversion of arachidonic acid to
leukotriene A4 (LTA4) by the enzyme 5-lipoxygenase is the first commited step in
leukotriene biosynthesis.
LT A4 is an unstable molecule and is hydrolyzed by LT~
hydrolase (LT A4H) to form Leukotriene B4 (LTB4). Alternatively, LTA4 can be
converted to LTC 4 through the addition of glutathione. LTD4 and LTE4 are the
metabolites of LTC4.

2

B. Leukotriene Receptors:

Though the role of leukotrienes in inflammatory diseases was known long ago, it
took considerable time to clone the receptors for these important mediators. There are
two known receptors for LTC4, (CysLTI and CysLT2), and for LTB4 (the high-affinity
receptor, BLTI and the low-affinity receptor, BLT2). The human CysLTI receptor was
cloned in 1999 (4) followed by the cloning of the human CysLT2 receptor in 2000 (5).
Human BLTI was the first to be cloned in 1997 (3), followed quickly by the murine
BL Tl in 1998 (6). During the analysis of the promoter region of BL Tl, Yokomizo et al.
identified an open reading frame (ORF) upstream of the BLTI gene. This ORF was
subsequently identified by this and three other groups as coding for a low-affinity
receptor of LTB4 and termed BL T2 (7-10). The homology ofthese receptors is shown in
Box 1 (11). BLT2 is the most conserved receptor in mice and human. The deduced amino
acid sequences of the BL Ts are shown in Figure 2 and Figure 3 as a snake diagram
depicting extracellular loops, transmembrane regions and intracellular loops. We
identified the transmembrane regions ofhBLTI and hBLT2 by molecular dynamic model
simulation methods (12). The transmembrane regions of murine BLTs are predicted from
hBLTs.

78.6%

92.7%

3

87.3%

73.4%

mBLT1
Figure 2: Snake Diagram of Human and Murine BLTl. Snake diagram (2D) are
shown for the human BLTI (top) and murine BLTI (bottom). The approximate lengths
of both the membrane-spanning regions and the extracellular loops were determined
using molecular dynamics simulations ofBLTl (Basu et al). Human BLTI was used as
an amino acid template to make murine BLTI. The amino acids that remain the same
remain labeled in white text with a black background, while the amino acids that are
different are labeled in white text with a red background.
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hBLT2

mBLT2
Figure 3: Snake Diagram of Human and Murine BLT2. Snake diagram (2D) shown
of the human BLT2 (top) and murine BLT2 (bottom). The approximate lengths of both
the membrane-spanning regions and the extracellular loops were determined using
molecular dynamics simulations ofBLT2. Human BLT2 was used as an amino acid
template to generate murine BLT2. The amino acids that remain the same remain labeled
in white text with a black background, while the amino acids that are different are labeled
in yellow text with a purple background.
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C. Expression and Function of BL Tl and BL T2:
Although BL T1 was long known to be a neutrophil chemoattractant receptor,
recent studies identified BLT1 expression on macrophages (13), smooth muscle cells
(14), endothelial cells (15) , activated T cells (16), mast cells (17), and dendritic cells
(18), considerably expanding the potential role of LTB4 . BL T2 has been shown to be
expressed widely in humans, with the spleen and peripheral blood leukocytes showing
the highest levels of expression (10), while the expression of BL T2 in the mouse has been
difficult to ascertain with several laboratories reporting variable results. Iizuka et al.
demonstrated expression of murine BLT2 as being highest in the small intestine and
lower in the skin by Northern blot. Using in situ hybridization, they were also able to
demonstrate the presence ofBLT2 in the skin. Upon performing RT-PCR based analysis,
they also found BLT2 in the colon and spleen at low levels (19). Another laboratory
confirmed the expression of BL T2 in the spleen, but was unable to detect any BL T2
signal in the skin (20). Using RT-PCR, expression ofBLT2 was demonstrated in murine
mast cells (17). In similar studies, our laboratory as well as another group investigating
BL T2 expression were unable to detect BLT2 expression in any of the cell types or
tissues tested (21, 22).

The reasons for these differences are unclear and must be

resolved. Results in this thesis show expression of BL T2 in cells derived from the bone
marrow.
The regulation patterns of BL T1 and BL T2 remain elusive. Recently,
dexamethasone has been shown to regulate the expression of BL T1 in a number of cell
types including human neutrophils, monocytes and T-cells (23, 24).

Stankova et al.

demonstrated that dexamethasone up-regulates BLTI in human neutrophils in a time and
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concentration dependent manner (24). Dexamethasone and IL-I0 were shown to upregulate BLTI expression in human monocytes, while IFNy, TNFa and LPS downregulated BLTI (23). Data demonstrating up-regulation of BLTI on CD8+ T effector
cells will be shown in Chapter II. Low levels of BLTl were discovered in resident
peritoneal macrophages in rats (25). However, macrophages elicited by proteosepeptone
showed an increase in the level of BL Tl expression in rats. LPS was demonstrated to upregulate BLTI in human umbilical cord vascular endothelial cells, while TNFa upregulated BL T2 (15). BLTl expression was also up-regulated in smooth muscle cells
upon treatment with

IL-l~

or LPS. When a plasmid over-expressing

IKK~,

an inhibitory

molecule for NFxB, was used in this assay, the BLTI up-regulation was blocked,
suggesting a requirement of the NF-xB pathway in BLTI regulation (14). Further
research is required to determine how the LTB4 receptors are regulated using both in vivo
and in vitro models.
Part of the regulation of BLTI is due to desensitization by phosphorylation of the
receptors and

~-arrestin

dependent internalization. Conflicting results about the

importance of phosphorylation in internalization of the receptors have been published
(26, 27). LTB4-induced internalization of BL Tl was demonstrated to occur in RBL-2H3
cells that express high endogenous levels of GPCR kinase 2 (GRK2), while
internalization of BLT 1 did not occur in COS-7 cells or HEK-293 cells which do not
over-express GRK2. BLTI internalization was blocked in RBL-2H3 cells when treated
with a dominant negative of GRK2. Internalization could be induced in HEK-293 cells

by co-expressing with wild-type GRK2. All this data demonstrated that phosphorylation
of BLTl is absolutely required for internalization of the receptor.
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They went on to

demonstrate that BLTI did not interact with arrestin either by fluorescence microscopy or
by coimmunoprecipitation. Finally, this group demonstrated that the C-tail of BLTI was
required for both GRK2 phosphorylation and internalization(26). In contrast, lala et al.
from our laboratory demonstrated that internalization of BLTI is phosphorylation
independent and

~-arrestin

dependent (27). BLTI mutants, which lack phosphorylation

sites in the C-tail (14 Ser/Thr are mutated to Ala) internalize through

~-arrestin.

This

mutant showed higher ligand-induced intracellular calcium release indicating a role for
receptor phosphorylation in desensitization process. Functional importance of the
internalization of BLTI was demonstrated by Gaudreault et al (28). They showed that
the internalization and activation of BLTI occur through Yes kinase, which was found to
be crucial for LTB4 induced degranulation of neutrophils.
Though BL Tl and BL T2 are GPCRs and bind the same ligand, some differences
III

G-protein specificity exist between these receptors. In addition, the usage of G-

Proteins varies in different cell types. The chemotaxis of CHO cells expressing either
human BLTI or human BLT2 was normal towards LTB 4. The chemotaxis was
completely abolished in cells treated with Bordetella pertussis toxin (PTX), which blocks
Gai/O-

dependent signaling. LTB4-induced intracellular calcium release was only partially

blocked when cells were treated with PTX, indicating that calcium response was
mediated by both PTX-sensitive and PTX-insensitive G proteins in CHO cells (3, 10). In
contrast, LTB 4-induced intracellular calcium release in human neutrophils was largely
sensitive to PTX treatment (29). The three intracellular loops of BLTI were shown to be
important for the binding of GUj and G 16 proteins in cells over-expressing BL TI along
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with either GUi or G 16 proteins in COS-7 cell lines. A short region in ICL3 was shown
to be critical in for the recognition of GUi protein (30)

In functional assays, BLT2 was shown to be about 100-fold less sensitive to LTB4
than BL Tl.

Of interest is the finding that human BL T2 also can bind and display

intracellular calcium release to l5(S)-hydroxyeicosatetraenoic acid (15(S)-HETE), l2(S)hydroxyeicosatetraenoic acid (12(S)-HETE), and 12(S)-hydroperoxyeicosotetraenoic acid
(12(S)-HPETE), while BLTI is very specific for LTB4 (10) demonstrating that though
both are considered LTB4 receptors, there are possible other functions of BLT2. These
two receptors may also be distinguished based on the pharmacological specificity of the
antagonists.

Most of the antagonists were developed based on inhibition of BLTI

function and, thus, are specific for this receptor. While a few BL T2 antagonists are
identified, dual inhibitors are not well characterized at this time. CPI05,696 and U75302
are both specific for BLTl, while LY255283 is specific for BLT2 (10, 31).
LTB4 mediated signal transduction pathways via BLT 1 such as chemotaxis (3),
degranulation (32), adhesion (33) and prolongation of the cell survival (34) were
functions previously attributed to BLTI in neutrophils.

Recent data has started to

delineate new roles for BLTI in neutrophils and in other cell types. For example, smooth
muscle cells have been shown to migrate and proliferate in response to LTB4 through
BLTI (14). Our laboratory has shown the presence of mRNA and LTB4 mediated
chemotaxis via BLTI in immortalized murine macrophages (35).
The expression of both BLTI and BLT2 was reported recently in human and
murine mast cells (17). This group showed the presence of mRNA for both receptors in
murine bone marrow-mast cells (mBMMC) and in human mast cells (hMC). They also
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demonstrated LTB4 induced chemotaxis of these cells. The chemotaxis was blocked by
either BL Tl or BL T2 specific inhibitors. It is interesting to note that mBMMCs
chemotaxed towards 12-(S)-hydroxyeicosotetraenoic acid, which is a BL T2-specific
agonist.

The data clearly suggested that both receptors are functional in mast cells.

Another new cell type that the LTB4 receptors have been described in is endothelial cells.
BL Tl and BL T2 were shown to be expressed in human umbilical vein endothelial cells
(HUVEC) at low levels. Up-regulation ofBLTl (mRNA and protein levels) were seen in
vitro when HUVEC cells were treated with LPS, while treatment with TNFa led to an
increase in BLT2 mRNA (15).

Expression on subsets of T cells has also been

demonstrated. It was shown that activating naIve T cells in vitro with anti-CD3 caused
up-regulation of BLTI in ThO, Thl and Th2 cells and these cells demonstrated
chemotaxis toward LTB 4, suggesting a functional role of BLTs in activated T cells. This
response was not seen in the mice lacking BLT 1 (16) highlighting the fact that LTB4
mediated signaling occurs via BLT1.
Recent experiments from our laboratory have demonstrated functional expression
of BLT1 on both mature and immature dendritic cells (18). It was shown that exposure
of immature dendritic cells (iDC) and mature dendritic cells (mDC) to LTB4 greatly
enhanced chemotaxis to the CCR7 ligands CCL 19 and CCL21 suggesting a priming
effect for LTB 4. In vivo, it was shown that mice in lacking both BL Tl and BLT2
(BLT1I2 KO) mDCs had a deficiency in trafficking to the popliteal lymph nodes when
compared to wild-type mDCs at 20 and 48 hours.

In contact hypersensitivity (CHS)

experiments, it was seen that BLT1I2 KO DCs very poorly initiated a CHS response
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when compared to wild-type DCs. These data together show that BLTI has a direct
effect in the control of adaptive immune responses.

D. Role of L TB4 and its receptors in various inflammatory diseases:
We now have a better understanding of expression patterns of BLTI and BLT2;
however the role of LTB4 in disease processes is yet to be fully uncovered. LTB4 is upregulated in many human diseases and can be found in atherosclerotic plaques (36, 37),
rheumatoid arthritis synovium (38), and in exhaled breath condensates in asthma patients
(39). Further illustrating the importance of LTB4 in human disease, recent population
studies have shown that certain LTA4H and FLAP polymorphisms in humans predispose
individuals to increased risk of myocardial infarction and stroke (40, 41). This means
that regulation of LTB4 biosynthesis is directly attributable to this increased risk. When
samples from chronic obstructive pulmonary disease patients were analyzed, it was found
that BLTI was very highly expressed and could be found in macrophages, CD8+ T cells
and neutrophils potentially implicating all three cell types in the disease process (42).

a) Atherosclerosis:
Mouse models of human disease have proven useful in delineating the role of
BL Tl in inflammatory diseases. Of these, models of atherosclerosis have demonstrated a
direct role ofBLTI in disease progression. Mice deficient in 5-LO were shown to have a
26-fold decrease in lesion development in an atherosclerosis model. In these studies, it
was shown that macrophages in the plaques abundantly expressed 5-LO (43). 5-LO
deficiency was also shown to protect mice from aortic aneurysm (44). Models utilizing a
BLTt antagonist, CP-I05,696, in Ldl -1- and ApoE -1- mice showed a reduced
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accumulation of CD 11 b+ cells in the lesions and limited lesion size (45). Our laboratory
was the first to demonstrate that the loss of BLTI protects mice from the development of
atherosclerotic disease. We found a significant decrease in plaque size in the early stages
of disease. The plaque analysis of BLTI-/- mice revealed a reduction in macrophage
accumulation compared to plaques of BLTI +/+ mice. It was also shown in the same
study that LTB4 up-regulated monocyte chemotactic protein-I, CD36, urokinase-type
plasminogen activator, colony stimulating factor-I, and osteopontin (35), all of which
already have an established roles in atherogenesis. Up-regulation of MCP-l by LTB4 was
confirmed in human monocytes (46).

This demonstrates that the LTB4-BLTI axis

provides an amplification loop to attract monocytes and macrophages to the site of plaque
formation and also leads to the destabilization of the plaque. Another cell type important
in the disease is the smooth muscle cells. The expression of BL Tl on smooth muscle
cells as stated before was shown and allowed for the chemotaxis of smooth muscle cells
towards LTB 4. This paper demonstrated loss of BLTI led to a decrease in the thickness
of smooth muscle cells in the plaque as well as T cells and macrophages (14). In addition
to being a key molecule in plaque progression, recent data have demonstrated that
symptomatic plaques express high levels of LTB4 which correlates with plaque
destabilization (47) a phenomenon that was confirmed when it was found that expression
of 5-LO and LTA4H in plaques led to their destabilization (48).

Population studies

recently have shown that polymorphisms in LTA4H and FLAP predispose the individual
to increased risk of myocardial infarct (40, 41).
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b) Asthma:

A vast amount of research involving LTB4 in asthma has been performed owing
to the fact that high levels of LTB4 are present in the airways of asthmatic patients (39).
In 2003, the discovery that CD8+ effector T cells express BLTI was made (49). It was
found that CD8+ effector T cells were able to chemotax towards LTB4, while naIve or
central memory T cells were unable. It was also shown that CD4+ Thl and Th2, but not
ThO T cells expressed BLTI as they left the lymphoid compartment and entered into
tissue (16). It was found in collaboration with our laboratory, that BLTI-/- mice have
decreased airway hyper-responsiveness in an ovalbumin-induced airway hyperresponsiveness (AHR) model (50).

Reconstitution of allergen sensitized BLTI +/+ T

cells fully restored AHR in BLTI-/- mice suggesting a role of BLTI in AHR.

A

reduction in goblet cell hyperplasia and interleukin-13 was also seen in BLTI-/- mice in
that study. This group performed another model of AHR which is mast cell-dependent.
In these studies, mice were sensitized with anti-ovalbumin (OVA) IgE and then
challenged with OVA in the airways. This model requires mast cells for the sensitization
from IgE and CD8+ cells for the reactive phase of the model. Wild-type mice develop
altered airway function, while CD8 -/- mice do not. CD8 -/- mice reconstituted with
CD8+ T cells develop AHR, while CD8 -/- mice reconstituted with BLTI-/- CD8+ T
cells do not develop AHR (51). This result was confirmed by another laboratory who
saw loss of AHR in another strain of mice deficient in BLTI (52). It was found that only
small populations of T cells express BLTI in healthy individuals.

The population

increases with Epstein - Barr virus infection and in asymptomatic allergy. The increase
in BLTI expressing T cells was seen only in the airway and not in the blood (53). A
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similar result was seen in asthmatic patients where BLTI expressing CD8+ T cells were
found in broncheo-alveolar lavage and in lung tissue, while no BLTI expressing CD8+ T
cells were found in healthy volunteers (54). These results suggest that BLTI might be a
useful target in asthma.
c) Other Inflammatory Diseases:

LTB4 has also been implicated in many other inflammatory diseases such as
inflammatory arthritis, a major focus of studies in this thesis (Chapter III). In addition,
LTB4 was also shown to be important in experimental autoimmune encephalomyelitis
(EAE) and peritonitis. It was found that the eosinophil recruitment in EAE is dependent
on LTB4 receptor ligation and further revealed a previously unrecognized role for
eosinophils in the pathogenesis of this disease (55). In a mouse model of peritonitis,
LTB4 and BLTI were found to play important roles in the recruitment and/or retention of
leukocytes, particularly eosinophils (56). Using BLTI deficient mice developed in our
laboratory, Liao et al. demonstrated an important role for LTB4 and BL Tl in autoimmune uveitis (57). Adoptive transfer experiments showed that expression of BL Tl is
important on both auto-reactive T cells as well as on innate immune effector cells
The major focus of our laboratory for the last 10 years has been to develop a
complete understanding of the structure/function, regulation and biological activities of
the LTB4 receptors. These studies used cell and molecular biological approaches as well
as mice deficient in the LTB4 receptors BLTI and BLT2 (12, 21, 27, 35, 58-60). The
work described in this thesis attempts to further our knowledge of the biology of LTB4
receptors by developing highly specific monoclonal antibodies for BLTI (Chapter II) and
demonstrating the functionalsignificance ofBLT2 (Chapter III).
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CHAPTER II

GENERATION AND CHARACTERIZATION OF
MONOCLONAL ANTIBODIES AGAINST HUMAN AND
MURINEBLTI

INTRODUCTION

Evolving technologies have allowed our laboratory and others to demonstrate the
presence of BLTI on cell types that had not previously been known to express BLTI in
the last few years (13-18). We have developed monoclonal antibodies to BLTl, which
allowed us to probe for the expression of BLTI and if any regulation patterns exist.
Chapter II will focus on the generation and characterization of these newly described
monoclonal antibodies.
The term monoclonal antibody simply means an antibody that has a defined
specificity because it arose from one original plasma cell. To produce a monoclonal
antibody, a vertebrate animal is immunized with the molecule of interest either purified,
conjugated to a carrier protein such as keyhole limpet hemocyanin (KLH), or on cells
expressing the molecule. Multiple rounds of immunization lead to the selection and
expansion of B cells that recognize the molecule in the spleen or lymph nodes. These
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tissues can be taken and the cells extracted and fused with a myeloma cell line using
polyethylene glycol (PEG). When grown in culture, the unfused plasma cells have a
limited life-time and die.

The myeloma cells used are unique in that they lack the

hypoxanthine-guanine-phosphoribosyltransferase (HGPRT) gene, which allows them to
make purines using hypoxanthine. In medium containing hypoxanthine, aminopterin and
thymidine (HAT), unfused myeloma cells do not survive due to the loss of the HGPRT
gene. A hybridoma fusion between a plasma cell and a myeloma cell will be immortal
and will contain a functional HGPRT gene, therefore, only these fused cells will survive.
These cells are diluted so that only one fusion will give rise to a population of cells
which make a monoclonal antibody.

The resultant monoclonal antibodies are then

screened against the antigen by enzyme-linked immunosorbent assays (ELISA) or
similar methods or, as in this assay, if the antigen is on a cell surface, flow cytometry can
be used.
Monoclonal antibodies are valuable and unique tools to detect and block the
antigen functions in biological systems. In research, monoclonal antibodies are used for
Western

blotting,

immunofluorescence,

immunohistochemistry,

immunoprecipitation, affinity chromatography and ELISA.

FACS,

Many ELISA kits are

available utilizing monoclonal antibodies such as for drug screening and pregnancy tests.
Monoclonal antibodies also have gained acceptance as treatments in human disease such
as cancer and rheumatoid arthritis and in organ transplantation. In the treatment of
cancer, there are two main types of monoclonal antibodies in use. The first are the naked
antibodies, which are not conjugated to another molecule. Some naked antibodies such
as Rituxan (61) and Campath (62) bind to the surface target and induce the host immune
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system to destroy the tumor. Other naked antibodies such as Herceptin (63), Erbitux (64)
and Avast in (65) are used to block surface proteins that are necessary for tumor cell
survival or growth. The other group of antibodies is the conjugated antibodies which are
attached to drugs, toxins or radioactive substances. Only the radiolabeled antibodies
Zevalin (66) and Bexxar (67) are currently approved for use in the clinic at this time; the
others are still in clinical trials. OKT3, an antibody against the T3 antigen on T cells, is
used to combat organ rejection in patients who have received an organ transplant (68).
Remicade (69), Humira (70), and Rituxan (71) are currently being used to treat
rheumatoid arthritis. Remicade and Humira are both antibodies against TNFa and have
been effective in combination with methotrexate in halting the progression of RA.
Rituxan targets B cells and has also shown promise in treating RA.
Given all the disease processes mediated by LTB4 and its receptors, monoclonal
antibodies against BLTl might prove to be useful in treatment of inflammatory diseases.
Although monoclonal antibodies have been available for human BLTl for several years
(72, 73), anti-BLTI antibodies that recognize BL Tl in small animals would be useful to

allow studies in mouse models of disease. Due to the potential usefulness of monoclonal
antibodies that recognize a common epitope between hBLTI and mBLTl, we initiated
experiments to produce these antibodies utilizing our BL T 1-/- mice. The technique that
was used had been performed successfully to produce L-selectin antibodies (74) which
involves the use of 300.19 mouse pre-B cells. The parental 300.19 cells were transfected
with HA-tagged hBLTI with an expectation that since hBLTI and mBLTI are highly
homologous, we would get antibodies that were cross-reactive for both. Unfortunately,
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immunization with 300.19 cells expressing HA-tagged hBLTI resulted in the isolation of
over 15 antibodies, all of which turned out to be specific for the HA-tag.
A new strategy was adopted, where red fluorescence protein (RFP) was fused at
the c-terminal end of BLTI without HA-tag. The hBLTI-RFP localized to membrane
suggesting fused RFP did not alter the folding of BLTI. The expression of hBLTI-RFP
was measured by the fluorescence of RFP. The cells expressing stable hBLTI-RFP
clonal lines were selected and experiments were repeated as described above. This
resulted in the production of over 30 monoclonal antibodies which all turned out to be
specific for hBLTI and showing no reactivity against mBLTI. Therefore, mBLTI fused
to tetramer RFP was expressed and put through the same protocol and this led to the
production of 8 mBLTI antibodies. These antibodies have allowed us to demonstrate the
expression of BLTI on human neutrophils and have allowed us to determine the
expression pattern of BLTI in different mouse tissues. Out of these results came new
data demonstrating differential expression of BLTI on macrophages depending on their
activation status and tissue localization.
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MATERIALS AND METHODS

Materials

CD3-FITC, B220-PE, NK1.I-PE, GR-I-PE, Siglec-F-PE, CD45.I-PE, CD45.2FITC, CD 11 b-FITC, CD 16-PE and Streptavidin-conjugated APC were all from BD
Pharmingen. GR-I-FITC was from Ebiosciences.

Generation of 300.19 Cells Expressing Murine and Human BL Tl

300.19 cells were maintained as a suspension culture in RPMI-1640 medium
containing 2 mM L-glutamine,

10% FBS,

I X

~-mercaptoethanol,

penicillin/streptomycin. Transfections were done by electroporation. 20

~g

and 1%

of pDSRED-

NI encoding human BLTI or mouse BLTI was electroporated into the cells and cells
were sorted by flow cytometric sorting. Single cell clones were made by limiting dilution
and the expression of functional receptor was tested by calcium flux in response to LTB4.

Immunization Protocol for 300.19 cells Expressing BL Tl

300.19 cells expressing hBL TI or mBLTI were harvested at 1500 rpm for 3
minutes and the cell pellet washed three times with PBS.

50 million cells were

resuspended in I mL of PBS and injected s.c. on the back ofBLTI-I- mice on the Balb/c
background. Within a week a large tumor grew at the site of injection and this tumor
resolved by two weeks. On day 14, another injection of 50 million cells was given i.p. as
a booster and again on day 21. On day 23, a sample of blood was taken and the plasma
isolated. The plasma was used to stain 300.19 parental cells and 300.19 cells expressing
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BLTI to check for specific staining for BLTI over background staining of the parental
cells. On day 24, the mice were sacrificed for hybridoma production.

Hybridoma Production

Mice were sacrificed and their spleens were removed. The spleens were placed in
a culture dish with 10 mL cDMEM-O (1% Nonessential Amino Acids, 2 mM Lglutamine, 50 /-lM 2-mercaptoethanol, 5000 units penistrep) and wire mesh size 60
(Sigma-Aldrich). The spleens were teased with two 21 gauge needles. The debris was
removed by pipetting through the mesh filter several times. The medium was transferred
into 50 mL Falcon tubes and the volume was increased to 45 mL with cDMEM. 0.3 mL
of FBS was layered under the medium to allow any clumps to settle out for about 3
minutes. The medium was carefully pipetted off from the FBS and placed in a new clean
50 mL tube and spun at 1500 rpm for 5 minutes. The supernatant was discarded and 45
mL of cDMEM-O was added to resuspend the cells. SP2/0 myeloma cells were taken and
placed in several 50 mL tubes and both SP2 and spleen cells were spun at 1500 rpm for 5
minutes. The supernatants were discarded and the spleen cells and SP2/0 were washed
twice. The SP2/0 and spleen cells were resuspended separately in 10 mL cDMEM-O and
enumerated. The SP2/0 and spleen cells were mixed at a 1: 1 ratio in a 50 mL tube and
the tube was filled with cDMEM-O and then spun at 1500 rpm for 5 minutes. The
supernatant was aspirated off and 1 mL of 50% polyethylene glycol (PEG) was added
slowly to the pellet over 1 minute drop-wise stirring after each drop. Then, another 1 mL
of prewarmed cDMEM was added to the pellet over 1 minute drop-wise stirring after
each drop. The addition of medium was repeated once more, and then 7 mL of cDMEM
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was added drop-wise over 2-3 minutes. The cells were spun at 1500 rpm for 5 minutes.
The supernatant was discarded and the pellet was resuspended in the volume of cDMEM20/HEPES (10mM HEPES) to give a concentration of 2.5 X 106 cells/mL. 100 ilL of
medium was added to each well of a 96-well plate. On day 2 of the experiment, 100 ilL

ofDMEM-20/HEPES/HAT (1 X HAT) was added to each well. On days 3,4,5, 7, 9 and
11, half the volume in the well was removed and another 100 ilL of DMEM-

20/HEPES/HAT was added to each well. On day 14, half the medium was removed from
each well and 100 ilL of DMEM-20/HEPES/HT was added. Starting on day 15, any
media changes were done with DMEM-20/HEPES.

Screening of Hybridomas

Hybridomas were allowed to grow until they reached approximately 50%
confluence. A sample of 10 ilL from the supernatant was removed and incubated with a
mixture of 5 X 10 5 parental 300.19 cells and 5 X 10 5 300.19 cells expressing HA-tagged
hBLTI in 500 ilL of PBS + 1% BSA and incubated for 1 h at 4°C. The cells were
washed with PBS + 0.1 % BSA and resuspended in 200 ilL of PBS + 1% BSA containing
1 ilL of goat anti-mouse IgG (Jackson Immunoresearch) and incubated for 45 m at 4°C.
The cells were washed once with PBS + 0.1 % BSA, resuspended in buffer and analyzed
by flow cytometry.

Cells were acquired on FACSCalibur (BD Biosciences) and

subsequent analysis was done with FlowJo version 4.3 (Treestar, Inc.).
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Monoclonal Antibody Purification and Biotinylation

Hybridomas were grown in RPMI-1640 medium containing 2% or less of FBS
and grown to a high concentration for high level production of antibody. 500 mL of this
medium was resuspended in 50% ammonium sulphate to precipitate the antibody. The
antibody was resuspended in 1 X PBS and dialyzed to remove the ammonium sulphate
and HPLC was performed on a Mono Q HR column (GE Healthcare). Peak protein
fractions were taken and used to stain BL Tl expressing cells to check antibody activity.
Those fractions that had the highest amount of activity were taken and biotinylated using
the EZ-link sulfo-NHS-LC-biotin kit (Pierce).

Random Chimeragenesis

Random chimeras between human and mouse BLTI were generated following a
protocol used previously to make chimeras of cAMP receptors (75).

The plasmid

pCDNA3.l+hmBl was used to produce the hBLTl and mBLTl chimeras. The sequence
for hemagglutinin-tagged hBLTl was cloned between the Nhe I and Hind III sites of
pCDNA3.l+. The sequence for mBLTl was then cloned between the EcoR I and Not I
sites of the plasmid containing hBL Tl. After the chimeragenesis procedure, the chimeric
receptor was flanked by Nhe I on the 5' end and Not I on the 3' end. The pcDNA3.l+
vector was linearized by double digestion with EcoR I and Hind III restriction enzymes,
which were located between both the genes. After testing by gel electrophoresis whether
digestion was complete, the enzymes were inactivated at 65°C for 30 minutes.

The

digested DNA was gel-purified. The digested DNA (750 ng) was used to transform E.

coli strains DH5a and TOPlO (Invitrogen) competent cells by heat shock and plated on
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LB plates containing ampicillin. 16 colonies were taken from the DH5a plate and 16
colonies from the TOPlO plate and analyzed by restriction analysis to check for a 1 kb
insert. 28 of these clones were determined to contain the correct size insert and were
digested separately with 3 restriction endonucleases; Xho I which is found at 243 bases in
mBLTl, Kpn I which is found at 517 bases in hBLTl, and EcoN I which is found at 728
bases in hBLTl. This analysis allowed us to break down the clones into 4 quadrants 1-4
where crossover occurred. 9 clones were located in quadrant 1, 6 in quadrant 2, 11 in
quadrant 3, and 6 in quadrant 4. The clones were confirmed by sequencing using primers
on either side of the multiple cloning site of the vector. 3 to 4 clones were sequenced
from each quadrant leading to the identification of 9 unique sites of crossover.

Staining of Human Neutrophils
Human volunteer blood was collected by venapuncture in 60 mL synnges
containing 5 mL of 3.8% w/v sodium citrate anticoagulant. An equal volume of 3%
Dextran T-500 in PBS was mixed and red blood cells were allowed to sediment for 30
minutes at room temperature. The leukocyte-rich plasma was aspirated above the red
cells with a syringe with tubing attached. The plasma was distributed in 15 mL volumes
into 50-mL disposable tubes and then under-laid with 10 mL of 1.077 g/mL density
Ficoll-Hypaque solution using a 20 mL syringe with tubing on the end. A layer of 1.105
g/mL Ficoll-Hypaque was then placed under the 1.077g/mL Ficolliayer. The tubes were
centrifuged for 30 minutes at 1000 g. Each tube contained a red cell pellet and two white
interface layers. The lower interface was taken which contained> 98% neutrophils. The
neutrophils were pooled into one tube to about 20 mL and 30 mL of PBS was added. The
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tubes were mixed and centrifuged at 1200 rpm for 12 minutes. The supernatant was
decanted and the tube was blotted on a paper towel leaving the white cell pellet. The
pellet was washed twice with PBS and centrifuged at 1000 rpm for 10 minutes. The cells
were resuspended in PBS and were counted. 500,000 cells were placed in several FACS
tubes and the cells were washed with PBS + 0.1 % BSA. The cells were then resuspended
in 0.5 mL of PBS + 1% BSA.

10 ~L of several culture supernatants from positive

hybridomas was added to separate tubes. The remaining procedures were done as above.

Murine Antibody Screening of Primary Cells and Cultured CD8+ T cells
Flow cytometry was performed using four samples from mice; blood, bone
marrow, spleen and lymph nodes. Mice were euthanized and the skin on the abdomen
and thoracic area were opened up to enable blood collection by cardiac puncture into
tubes containing heparin (MP Biomedicals). The entire ventral surface from under the
jaw of the mouse down to the base of the hind-limbs had the skin laid open to reveal the
lymph nodes. The superficial cervical, axillary, brachial and inguinal lymph nodes and
spleen were removed and the leukocytes were isolated. Bone marrow was isolated from
the femurs and tibias and leukocytes were isolated. These samples were resuspended in
100

~L

of PBS + 1% BSA containing 1

~L

of biotinylated 3D7 and a number of

conjugated cell surface markers. The tubes were then incubated for Ih at 4°C and washed
with PBS + 0.1 % BSA. The cells were resuspended in 200
containing 1

~l

~L

on PBS + 1% BSA

of streptavidin-conjugated APC and incubated for 45m at 4 T. 2 mL of

BD FACS Lysing Solution was added to blood samples and 1 mL added to the remaining
samples and incubated at room temperature for 1h. The cells were washed, resuspended
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and analyzed by flow cytometry. This same procedure was used to stain CD8+ effector
and central memory T cells.

Dexamethasone Up-regulation of BLTI in CD8+ T cells

Mononuclear cells collected from lymph nodes and spleen of OT -1 TCR
transgenic mice were stimulated with 1 /lg/mL of SIINFEKL peptide for 90 min. After
washing, cells were cultured for 2 days in complete media (RPMI-1640 medium
supplemented with 10% heat-inactivated FCS, 50 /lM 2-ME, 100 U/mL penicillin G, 100
/lg/mL streptomycin, and 10 mM HEPES). Cells were then washed and cultured in
complete media containing 20 ng/mL of either recombinant murine IL-12 for generation
ofTEFF cells or IL-15 for TeM cells. To address the effect of DEX on memory CD8+ T
cells, dexamethasone 21-phosphate disodium salt (DEX; Sigma-Aldrich) was added to
the culture medium during differentiation of these cells. Medium containing cytokine
and/or DEX were changed everyday. After 5 days, cultures were shown to contain>
99%

a~/CD8+

T cells. CD4+, CDllc+, NK1.1+ or y8+ cells were <0.1%. The cells

were >90% either CD8+ effector memory or central memory cell phenotype, as shown by
the CD62L1CCR7 cell surface marker. TEFF cells derived through this protocol showed
phenotypic and functional characteristics of effector memory CD8+ T cells in vivo. Cells
were used between days 5 and 8 of culture after addition of either IL-2 or IL-15.
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RESULTS

Generation of hBLTl and mBLTl Specific Monoclonal Antibodies

300.19, a murine pre-B cell line expressing high levels of human BLTI was used
to immunize BL Tl deficient mice in BALB/c background as described in methods. Two
days before sacrifice, a blood sample was taken and the plasma was analyzed for
reactivity to hBLTI. This analysis is shown in Figure 4, where the red line represents
parental 300.19 cells and the blue line represents 300.19 cells expressing hBLTl. As
expected, the plasma from immunized mice showed reactivity against 300.19 cells.
However, 300.19 cells expressing hBLTl showed a considerable increase in mean
fluorescence demonstrating specific activity against hBLTI.
Based on this observation, spleens were removed from these mice and fused with
SP2/0 myeloma cells to form hybridomas as described in methods.

The cells were

diluted at a ratio (2.S X 10 5/mL) so that positive wells should arise from only one
hybridoma, thereby making it monoclonal. As the cell growth in a 96-well plate reached
approximately SO% confluence the supernatants were taken and analyzed by flow
cytometry. A simple screening method using equal amounts of parental 300.19 cells and
300.19 cells expressing HA-tagged hBLTI was used for rapid detection of positive
clones (Figure S). By this method, we anticipated no reactivity when the supernatants
contained no antibody (negative, Figure Sa) whereas a complete shift indicated a 300.19
cell specific antibody (Figure Sc) and half the cells reacting indicated the presence of a
potential BLT1 specific antibody (Figure Sb).
scenarios are shown in Figure 5 for hBLTl.
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Figure 4: Plasma Screening of hBLTl Immunized Mice. BLT1 -1- Balb/c mice were
immunized with 300.19 cells expressing hBLTl and boosted twice with the same cells.
Plasma was isolated from one of these mice and was used to stain 300.19 parental cells
(red line) and 300.19 cells expressing hBLTl (blue line).
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Figure 5: Screening Strategy for Detecting Hybridoma Supernatants with hBLT1Specific Antibodies. The supernatant of hybridoma culture (10 JlL) was added to an
equal mixture of 300.l9 parental cells and 300.19 cells expressing HA-tagged hBLTl.
Goat anti-mouse IgG-FITC was used as secondary antibody. The 300.19 cells were
analyzed on the FLI gate for FITC staining. Three representative results are shown. a)
Culture supernant with no detectable antibody b) Culture supernatant containing an
antibody that recognized 300.19 cells. c) Parental 300.19 antibody.
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Cells from individual wells that showed hBL T1 specific staining (pattern as seen
in 5b) were further expanded and antibody specificity of the supernatants to hBL T 1 was
confirmed by staining parental 300.19 and 300.19 cells expressing hBL T1 separately.
Many of these were further analyzed for reactivity against other cell lines expressing
human or murine BLT 1 as well as human and murine neutrophils. The results of these
analyses are shown in Table 1 where the level of binding was rated as - for no binding or
+ to +++++ for how well they stained cells expressing the indicated forms of BLT1. As
seen in Table 1, these monoclonal antibodies stained hBL T1 fused to RFP in 300.19 cells
and HA-tagged hBLT1 in rat basophilic leukemia (RBL) cells. There was, however, no
staining when the monoclonal antibodies were tested against 300.19 cells expressing HAtagged mBLT1. In addition, zymosan-elicited murine neutrophils which are known to
express BL T1 at high levels also showed no detectable staining.
Since monoclonal antibodies to mBLT1 would be a very useful tool to investigate
the role of BLT1 in mice, the same technique as above was used with 300.19 cells
expressing mBLT1. The resulting antibodies from this experiment are shown in Table 2.
All these antibodies were found to be specific for mBLT1 showing no staining for cells
expressing hBLT1.
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Clone 10
2A8
2A8-SC2
5B10
6H12
7A5
7G6
7G6-SC2
8E8
8H7
9A4
9B10
9E12
9G8
10C8
10C8-SC3
1101
11G3
12B1
12F1
13C3
13C3-SC1
13E2
13E2-SC8
13F2
13F8
14A7
1409
14E8
14E8-SC6
14F11
15A3
15E6
16A12
1608
16A10
1602
17E6
17G4
16F1
17F9
6F4
3G9

300.19
RBL
hBLT1-RFP hBLT1
++++

N.D.
+++
++++
+
+++
++++
++++
+++
+++
+++
+++
++++
+++
+++++
++++
+
+
++
+++
++++
+++
++++
++++
+
++
+++
+
+++
+++
+++
++
++++
++++
++
++

N.D.
N.D.
N.D.
++++
+
+

+++
+++
+
+++
+
++
++
+
++
++
+
++
++
++
++++
+++
+
+
+
+
+++
+
+++
+++
+
++
+
+
++
+

N.D.
N.D.
N.D.
N.D.
N.D.
N.D.
N.D.
N.D.
N.D.
N.D.
N.D.
N.D.

300.19
mBLT1

Murine
Human
300.19
Neutrophil Neutrophil hBLT1-DG

-

-

++

+
N.D.
-

-

++

N.D.
N.D.

N.D.
N.D.

N.D.
N.D.
N.D.
N.D.
N.D.
N.D.
N.D.

-

N.D.
N.D.
N.D.
N.D.
N.D.

-

N.D.
N.D.

-

N.D.

N.D.

+

N.D.
N.D.

-

N.D.
N.D.
N.D.
N.D.

++

-

-

N.D.
N.D.
N.D.
N.D.
N.D.
N.D.
N.D.
N.D.
N.D.
N.D.
N.D.
N.D.
N.D.
N.D.
N.D.

N.D.
-

N.D.
N.D.
N.D.
N.D.
N.D.
N.D.
N.D.
N.D.
N.D.
N.D.
N.D.

-

N.D.
N.D.

++

N.D.
N.D.

N.D.
N.D.
N.D.
N.D.

-

N.D.

+

N.D.
N.D.
N.D.
N.D.
N.D.
N.D.
N.D.
N.D.
N.D.
N.D.

++++
++++
+++
++++
++
+++
+++
+++
+++
++++
+
++++
++++
+++
+++++
+++++
++
+++
++++
+++
+++++
++
+++
+++++
++
++++
+++++
++++
++++
+++++

N.D.
N.D.
N.D.
N.D.
N.D.
N.D.
N.D.
N.D.
N.D.
N.D.
N.D.
N.D.

Table 1: Human BLTI Monoclonal Antibody Species Specificity. A panel of hBLTl
monoclonal antibodies were used to stain hBLTl fused to different tags and expressed in
various cell types or primary cells. For each cell type, each antibody is ranked as N.D.
for not determined, - for negative, + for mean fluorescence (MF) of 20-1 00, ++ for MF of
101-250, +++ for MF of251-500, ++++ for MF of501-1000 and +++++ for MF of 1001
or more.
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2E4
3A5
307
4A12
5E6
6B1
6E2
6F11

300.19 mBLT1 300.19 hBLT1
+
++

-

+++++

-

++

+++++

-

+++++

-

+
+++

Table 2: Reactivity of Murine BL Tl Monoclonal Antibody. A panel of
mBLTl monoclonal antibodies was used to stain cells expressing mBLTl or
hBLTl tagged with RFP. For each cell type, the antibody is ranked as N.D. for
not determined, - for negative, + for mean fluorescence (MF) of 20-100, ++ for
MF of 101-250, +++ for MF of 251-500, ++++ for MF of 501-1000 and +++++
for MF of 1001 or more.
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Analysis of parental 300.19 cells (solid line), 300.19 cells expressing hBLT1
(dotted line) and 300.19 cells expressing mBLT1 (dashed line) stained separately with 3
different antibodies is shown Figure 6. These three cell lines were stained with 12CA5,
an antibody that recognizes the HA epitope tagged to hBLT1 and mBLT1 (Figure 6a).
As seen in Figure 6a, the parental 300.19 cells did not stain with 12CA5, whereas cells
expressing the HA-tagged versions ofhBLTI and mBLT1 stained positive for 12CA5. In
Figure 6b, 6H 12 (a hBL T 1 specific mAb) was used to stain the cell lines and only stains
300.19 cells expressing hBLTl. In contrast the 6B1 (a mBLT1 specific mAb) reacted
with only 300.19 cells expressing mBL T1. These data are representative of all the mAbs
tested against hBLTI and mBLTI and demonstrate that the antibodies produced are
species specific for the type of BL T 1 used to immunize the mice.

Epitope Mapping of hBL Tl Monoclonal Antibodies

We next wanted to determine epitope specificity of anti-BLT1 antibodies. To
accomplish this, a series of chimeras between hBLT1 and mBLT1 were made using
random chimeragenesis. This method takes advantage of the ability of E. coli to carry
out homologous recombination between related sequences in vivo.

The hBL T1 and

mBLT1 proteins are highly homologous with ~ 75% identity. A flow diagram for the
strategy is shown in Figure 7 and the methodology described in the Methods section.
Utilizing unique restriction enzyme sites in either gene, we were able to divide the
resulting chimeras into quadrants where crossover occurred. Based on this information,
several chimeras were sequenced to determine the exact region of crossover and
representative chimeras are shown in Figure 8, where the hBL TI region is shown in pink
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and the mBL Tl region is shown in blue. The designation below each chimera denotes
where the protein sequence ends for hBL Tl and begins for mBLTl. Four chimeras
(BlC7, BlC29, BlC22, and BlC8) were transiently transfected into HEK-293 cells and
used to test binding of the human mAbs by flow cytometry. The data shows that all
chimeras reacted with l2CA5 antibody at similar levels (Figure 9a and 9c) indicating
normal surface expression of each chimera. In contrast, only hBL Tl, B 1C7 and B 1C29
reacted with 6H12, the human BLTI mAb, but not with mBLTl, BlC22 or BlC8 (Figure
9b, 9d and ge). Since the antibody can only react with extracellular surface domains,
these results suggest that the extracellular loop 2 (ECL2) is likely the binding site for the
monoclonal antibodies. As this region is replaced with the corresponding region from
murine BLTl, loss of binding occurs. Quantification of the data with other hBLTl mAbs
shown in Figure 6e confirms the finding with 6H12 and suggests that all hBLTl
antibodies are likely to react with the similar epitopes located on ECL2. In summary,
l2CA5 is shown to stain all six chimeras equally well, as expected, while 6H12, 2A8 and
l3F2 only show positive staining for hBLTl, BlC7 and BlC29.
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Figure 6: Flow Cytometric Analysis of Species Specific Monoclonal Antibody.
Flow cytometry utilizing three cell lines is shown: 300.l9 parental cells (solid line),
300.l9 cells expressing hBLTl (dotted line) and 300.l9 cells expressing mBLTI (dashed
line). a) Both the cell lines expressing HA-tagged receptor demonstrated positive
staining for 12CA5, while 300.l9 parental cells are negative. b) HA-tagged hBLTl only
showed positive for 6H12 (human specific BLTI mAb) , where the 300.l9 cells
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expressing hBLTI as well as parental 300.19 showed negative.
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Figure 7. Strategy for Random Chimeragenesis of hBLTl and mBLTl. hBLTl was
first cloned into the pcDNA3.l vector at Nhe I and Hind III restriction sites. mBLTl was
next cloned into above construct at EcoR I and Not I sites The pcDNA3.1 vector
containing hBLTl and mBLTl sequence was linearized by BamHl. The linerized
plasmid (750 ng) was transformed into DH5a and TOP 10 ~. coli strains. Only plasmids
encoding chimeric receptors form colonies.
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Figure 8: Cartoon Representation of BLTI Chimeric Receptors. Chimeric receptors
resulting from random chimeragenesis were sequenced to determine the exact region of
crossover between hBLTl and mBLTl. Since hBLTl was on the 5' end of the coding
region, all chimeras begin with hBLTl. Wild-type hBLTl is shown in pink:. Wild-type
mBLTl is shown in blue. Chimeras between hBLTl and mBLTl represented by the both
colors. The total amino acid length of the chimera and at which amino acid residue of
hBLTl ends and mBLTl begins is noted under each construct.
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Figure 9: Epitope Mapping for hBLTl and mBLTl Monoclonal Antibodies: HEK293 cells were transiently transfected with HA tagged hBLTl (green line), B 1C7 (blue
line), BIC29 (red line), BIC22 (pink line), BIC8 (light green line) or mBLTl (light blue
line). 12CA5 and several hBLTl monoclonal antibodies were used to stain these transient
transfections. 12CA5 is a positive control for each transfection (a and c). Staining with
6H12 is shown in b and d, where only hBLTl , BIC7 and BIC29 demonstrate positive
staining, while BIC22, BIC8 and mBLTl are negative. Quantification of the percentage
of positive cells for 12CA5 staining and two different hBLTl antibodies is shown in f.
Once again, 12CA5 is shown to stain all six equally well, while 2A8 and 13F2 only show
positive staining for hBLTl , BIC7 and BIC29.
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Characterization of hBL Tl Monoclonal Antibodies
To test whether these monoclonal antibodies could bind primary human cells, a
blood sample was taken and the neutrophils were isolated and stained with a sampling of
the monoclonal antibodies. 300.19 cells expressing hBLTl were used as controls in the
same experiment. All eight antibodies stained 300.19 cells expressing hBLTl very well,
however, only five of the eight stained primary human neutrophils. To test whether this
staining difference was due to differential glycosylation status of hBLTl in murine B
cells versus human primary neutrophils cells, a deglycosylation mutant of hBLTl was
generated by standard site directed mutagenesis protocol (Jala et al), in which the two
glutamine glycosylation sites were mutated to glutamate (N2Q and NI64Q). A stable
300.19 cells expressing N2Q- NI64Q-hBLTl (hBLTI-DG) was generated and tested for
antibody specificity. A panel of antibodies were used to stain the 300.19 cells expressing
the deglycosylation mutant of hBLTl and as seen in Table 1 all the antibodies tested
stained the deglycosylation mutant at equal or better levels than the wild-type hBLTl
line.

Differential Expression of Murine BLTl Detected by Monoclonal mBLTl
Antibodies
Using the same hBLT1/mBLTl chimeras, it was shown that the murine BLTI
monoclonal antibodies were also specific for the ECL2 region of the protein (data not
shown). Using these mBLTl monoclonal antibodies, the expression pattern of murine
BLTI was demonstrated by flow cytometry. BLTI-I- mice served as a negative control to
determine the precise expression in primary cells from mice. We also analyzed the
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expression of BLTI in BLT2-/- mice as the BLTI promoter is located in the BLT2
coding region and the expression pattern ofBLTI may be altered in BLT2-/- mice. Thus,
the mAbs are a valuable tool to examine this aspect of BLTI regulation as this will
become important for studies described in Chapter III. We analyzed the expression of
mBL Tl in various primary cells isolated from murine blood, bone marrow, lymph nodes
and spleen.
a) Neutrophils:

The expression of BLTI on neutrophils from murine blood, bone marrow, lymph
nodes and spleen of wild-type, BLT2-/- and BLTI-/- mice is shown in Figures 10 and II.
The gating strategy by forward and side scatter for neutrophils is shown in Figure 10a for
blood, Figure 10c for bone marrow, Figure 11 a for spleen, and Figure 11 c for lymph
nodes. This gated population was further analyzed for expression of GR-I-FITC, a major
neutrophil marker (Figures lOb, lOe, 11 b, 11 e), and GR-1 + cells are analyzed for the
expression of BLTI (Figures lOc, lOf, lIc, 11 f). BLTI-/- cells are represented by a red
line, BLT2-/- by a blue line and wild-type (BLTl/BLT2+/+) mice by a green line. The
highest expression of BL Tl was seen in blood and the bone marrow neutrophils (Figure
10c and 10f). Though few neutrophils are present in the spleen and lymph nodes, they
showed positive staining for BLTI in GR-l + cells in Figures 11 c and 11 f suggesting the
presence of mBLTl at low levels compared to blood and bone marrow cells.
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Figure 10: BLT1 Expression on Neutrophils from Murine Blood and Bone Marrow.
Whole blood of mice was collected from C57/B16 mice by cardiac puncture. Tibias and
femurs were removed from mice and flushed with RPM!. The bone marrow was
uniformly resuspended, filtered and washed. 1 X 106 bone marrow cells were taken for
analysis. 50 JlL of blood was taken directly for analysis. Blood (a,b and c) and bone
marrow (d,e and f) were stained with 3D7 and GRI-FITC. Neutrophils were gated using
characteristic forward and side scatter in a and d. Cells which stained positively for the
GRI-FITC marker were gated in band e. GRI-FITC positive neutrophils were analyzed
for their expression of BLTI in c and f. Staining for BLTI -/- mice (red line), BLT2 -/mice (blue line) and BLTlIBLT2 +/+ mice (green line) showed BLTI -/- mice stain
negatively with 3D7, while BLTlIBLT2 +/+ and BLT2 -/- both stain well in both bone
marrow and blood.

40

4

10 i 30.8
800
C
Q)
Q)

103

X

ro

~60

~

ffi1Q2

(jJ
(jJ

0

>R
0

400

Q..
(J)

40
10 1

20(1)
(Jl

0

200 400 600 800 1000

10 ~

20
0

FSC-H

104
Q)

0

Z

10.6

103

10

100 1000 10000
BLT1

10

100 1000 10000
BLT1

80
X

ro

~60

ffi1Q2

(jJ

1

100

e

I

0(jJ

0

200 400 600 800 1000

FSC-H

"'0

c

80

I

0600

100

·b

0

0>R

40

..c

Q.

101

E

>.

.....J

10°

200 400 600 800 1000
FSC-H

0

200 400 600 800 1000
FSC-H

Figure 11: BLTI Expression on Neutrophils from Spleen and Lymph Nodes. Spleen
and lymph nodes were removed from C57/Bl6 mice and single cell suspensions were
made by passage through nylon mesh. 1 X 106 spleen and lymph node cells were taken
for analysis . Spleen cells (a, b and c) and lymph node cells (d, e and f) were stained with
3D7 and GRI-FITC. Neutrophils were gated using characteristic forward and side scatter
in a and d. Cells which stained positively for the GRI -FITC marker were gated in band
e. GR 1-FITC positive neutrophils were analyzed for their expression of BLT 1 in c and f.
Staining for BLTI -/- mice (red line), BLT2 -/- mice (blue line) and BLTl /BLT2 +/+
mice (green line) showed the background staining for BLTI -/- mice with 3D7 increased,
while BLTlIBLT2 +/+ and BLT2 -/- both demonstrated positive staining for BLTl.
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b) Eosinopbils:

Eosinophils were also found to express BLT1 at high levels in the blood and at
lower levels in bone marrow, spleen and lymph nodes.

The gating strategy for

eosinophils is shown in 12a (blood), 12d (bone marrow cells), 13a (spleen) and 13d
(lymph nodes) where all cells were plotted for GR-1-FITC expression on the y-axis and
side scatter on the x-axis. Cells which were GR-1-intermediate and showed a high side
scatter were gated as eosinophils. The gate was then analyzed in 12b, 12e, 13b and Be
for the expression of Siglec-F-PE, which is a specific marker for murine eosinophils.
Siglec-F positive cells were finally analyzed for the expression of BLTI in 12c, 12f, 13c
and 13f. In summary, expression ofBLTl is high in the blood (Figure 12c) and is readily
detectible in the bone marrow, spleen and lymph nodes (Figure 12f, 13c and 13t).
c) Macropbages:

Macrophages were analyzed to detect the expression of mBLTl in the bone
marrow, followed by the blood, spleen and lymph nodes of wild type, BLT1-/- and
BLT2-/- mice. The gating strategy is shown in 14a (blood), 14d (bone marrow), 15a
(spleen) and 15d (lymph node), where all cells were initially plotted by forward and side
scatter. The gated cells were then analyzed by fluorescence of CD 11 b-FITC and CD16PE (Figure 14b, 14e, 15b and 15t). CDllb is a marker for macrophages and neutrophils
which were separated by the forward and side scatter. Those cells which showed high
fluorescence for CDllb and CD16 were gated (Figure 14b, 14e, 15b and 15t)and
analyzed for the expression ofBLTI (14c, 14f, 15c and 15t). The highest expression of
BLT1 in macrophages was seen in the bone marrow (Figure 14t). BLT1 expression was
also present in the blood and even though macrophages are a rare population in the spleen
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and lymph node, positive staining was seen in those locations as well. It was observed
that the expression of mBLTl decreased in bone marrow of BL T2-/- mice compared to
wild-type mice. Whether this difference has any functional impact needs to be studied
further. Analysis of macrophages with intermediate levels of CD 16 and CD 11 b staining
showed not detectable BL Tl expression (Figure 16).

d) Natural Killer Cells:
The expression of BLTI was analyzed on natural killer cells (FigureI7) from
blood, bone marrow, spleen and lymph nodes. Natural killer cells were gated from the
side and forward scatter analysis as shown in 17a. The gated cells were then analyzed by
NK1.1-PE, a natural killer cell marker, and CD3-FITC (17b) and the NK1.1 + CD3- cells
were taken as natural killer cells and were analyzed for their expression ofBLTI in blood
(17c), and bone marrow (17d). Natural killer cells that express the T cell marker CD3 are
termed natural killer T cells. Using a similar gating strategy as NK cells, natural killer T
cells were tested for BLTI expression. NKT cells were gated by forward and side scatter
in 17a with the same gate as NK cells. The gated cells were again analyzed with NK1.lPE and CD3-FITC, but the cells which stained for both CD3 and NK1.l were taken as
NKT cells. The expression in blood (17e) and bone marrow (17f) is shown and again, no
positive staining was seen for BLTI in the sites tested.
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Figure 12: BLTI Expression on Eosinophils from Blood and Bone Marrow. Whole
blood cells and bone marrow cells were isolated from C57/Bl6 mice as described in
Figure legend 11. Blood (a,b and c) and bone marrow (d,e and f) were stained with 3D7,
GRI -FITC and Siglec -F~PE. Eosinophils were gated as ORl intennediate and S C high
in a and d. Cells which stained positively for the Siglec-F-PE marker were gated in band
e. Siglec-F positive eosinophils were analyzed for their expression of BLTI in c and f.
Staining for BLT I -1- mice (red line), BLT2 -1- mice (blue line) and BLTlIBLT2 +1+
mice (green line) demonstrated a large increase in staining of BLT 1IBL T2 +1+ and BLT2
-1- mice over BLTI -I· mice in the blood. The background staining of BLTI -1- mice
increased in the analysis of bone marrow, but positive staining is visible for B TlIBLT2
+1+ and BLT2 -1- mice.
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Figure 13: BLTI Expression on Eosinophils from Spleen and Lymph Nodes. Spleen
and lymph nodes were isolated as described in Figure 12 legend. Spleen cells (a,b and c)
and lymph node cells (d,e and f) were stained with 3D7, GRl -FITC and Siglec-F-PE.
Eosinophils were gated as GRl intermediate and side scatter high in a and d. Cells which
stained positively for the Siglec-F-PE marker were gated in b and e. Siglec-F positive
eosinophils were analyzed for their expression of BLT 1 in c and f. Staining for BLTI -1mice (red line), BLT2 -I· mice (blue line) and BLTI /BL 2 +1+ mice (green line) showed
background staining for BLTl -/- mice with 3D7 increased, while BLTlIBLT2 +1+ and
BLT2 ·1· both demonstrated positive staining for BLTl.
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Figure 14: BLTI Expression on CDllb High and CD16 High Macrophages from
Blood and Bone Marrow. Blood (a,b and c) and bone marrow (d e and f) were tained
with 3D7, CDllb-FIT and CD16-PE. Macrophages were gated by characteristic
forward and side scatter (a and d) . Cells which stained CD 11b high and CD 16 high were
gated (b and e). CDllb high and CD16 high macrophages were analyzed for their
expression ofBLTl (c and f) . Staining for SLTI -1- mice (red line), BLT2 -1- mice (blue
line) and BLTI /BLT2 +1+ mice (green line) demonstrated a noticeable increase in
taining of BLT1IBLT2 +1+ and BLT2 -1- mice over BLTI -1- mice in the blood. A
definite increase in BLI1 staining was seen in bone marrow for BLTlIBLT2 +1+ mice
and a moderate increase in BLT2 -1- mice.
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Figure 15: BLTI Expression on CDllb High and CD16 High Macrophages from
Spleen and Lymph Nodes. Spleen cells (a,b and c) and lymph node cells (d, and f)
were stained with 3D7, CDllb-FITC and CD16-PE. Macrophages were gated by
characteristic forward and side scatter in a and d. Cells which stained CD 11b high and
CD 16 high were gated in band e. CD 11 b high and CD 16 high macrophages were
analyzed for their expression of BLTI in c and f. Staining for BL Tl -/- mice (red line),
B T2 -/- mice (blue line) and BLTlIBLT2 +/+ mice (green line) showed high
background staining for BLTI -/- mice and an increase in staining is seen in macrophages
from BLT IIBLT2 +/+ and BLT2 -/- mice.
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Figure 16: Lack of Detectable BLTI Staining on CDUb Intermediate and CD16
Intermediate Macrophages. Blood (a,b and c), bone marrow (d), spleen cells (e) and
lymph node cells (f) were stained with 3D7, CD ll b-FITC and CD16-PE. Macrophages
were gated by characteristic forward and side scatter in a. Cells that were CD 11 b
intermediate and CD 16 intermediate were gated in b. CD 11 b intermediate and CD 16
intermediate macrophages were analyzed for their expression of BLTI in c,d,e and f.
Staining for BLT I ./- mice (red line), BLT2 -/- mice (blue line) and BLTl /BLT2 +/+
mice (green line) demonstrated no detectable expression of S LT I on CDIlb intermediate
and CD 16 intermediate macrophages in any sample tested.
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Figure 17: Lack of Detectable BLT I Staining on Natural Killer or Natural Killer T
Cells. Blood (a,b,c and e) and bone marrow (d and t) were stained with 3D7, CD3-FITC
and NKl.I -PE. Natural killer and natural killer T cells were gated by characteristic
forward and side scatter in a. Cells which stained NKl .l positive and CD3 negative and
cells which stained NKI.2 pos itive and CD3 positive were gated in b. NK l .l positive
natural killer cells were analyzed for their expression of BLTl in blood (c) and bone
marrow (d) . NKl.l and CD3 positive natural killer t cells were analyzed for their
expression ofBLT I in blood (e) and bone marrow (t). Staining for BLTI -/- mice (red
line), BLT2 -/- mice (b lue line) and BLT lIBLT2 +/+ mice (green line) demonstrated no
detectable expression of BLTl on natural killer cells or natural killer T cells in blood or
bone marrow.
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e) B cells:
BLTl had not been identified on B cells previously and our tests showed no
expression on B cells at any site tested. The gating strategy is shown in Figure ISa from
all cells being shown by forward and side scatter.

The gated cells were analyzed for

their expression of B220, a B cell marker (Figure ISb).

B220 positive cells were

analyzed for their expression of BLTI in blood (lSc), bone marrow (lSd), spleen (ISe)
and lymph nodes (lSf). There was no detectable expression of mBLTl observed in B
cells from any locale.
f) T cells:

Expression of BL Tl has been shown in populations of activated T cells. Analysis
of T cells in various sites in the mouse, however, demonstrated no detectable expression
ofBLTI on T cells at any site tested. The same forward and side scatter gate was used in
(Figure 19a) as for the B cells, but the gated cells were tested for their expression of
CD3-FITC, a T cell marker,

(Figure 19b). CD3 positive cells were again analyzed for

their expression of BL TI in blood (Figure 19c), bone marrow (Figure 19d), spleen
(Figure 1ge) and lymph node (Figure 19f).
Recent studies show that activated effector T cells, but not naIve T cells express
BLTl at detectible levels (l6). It is apparent that the T cells analyzed in our unstimulated
mice are not effector cells. To test for BLTI expression on activated T cells, we received
CDS+ effector and central memory T cell cultures from the Gelfand laboratory. These
cells were stained with the naked 3D7-mBLTl antibody along with CDS-PE or CD62LPE. CDS+ effector T cells should stain highly with CD62L, while central memory cells
stain CD62L low. In Figure 20, staining with 3D7-mBLTl and CDS shows a definite
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increase in staining for effector T cells (31 % in a) when compared to central memory T
cells (0.3 %). A similar result is seen upon staining with 3D7-mBLTI and CD62L,
where effector T cells are CD62L high and demonstrate 28% positive staining for BLTI,
while central memory T cells are CD62L low and shows only a background level of 0.4%
positive staining. In studies carried out in Dr. Gelfand's laboratory using the biotinylated
3D7-mBLTI antibody, dexamethasone was shown to up-regulate the expression ofBLTI
in CD8+ effector and but not in CD8+ central memory T cells (Figure 21). Furthermore,
the increase in expression was correlated with increased functional activity as measured
by calcium mobilization and ERK-activation (data not shown).
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Figure 18: Lack of Detectable BLTI Staining on B cells. Blood (a,b and c), bone
marrow (d), spleen cells (e) and lymph node cells (f) were stained with 3D7 and B220-PE.
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B220 po itive were gated in (b). B220 positive B cells were analyzed for their expression
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and BLTl /BLT2 +/+ mice (green line) demonstrated no detectable expression ofBLTl
on B cel ls in any sample tested.
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Figure 19: Lack of Detectable BLTI Staining on Resting T cells. Blood (a,b and c),
bone marrow (d), spleen cells (e) and lymph node cells (f) were stained with 3D7 and
B220-P . T cells were gated by characteristic forward and s' de scatter in a. Cell which
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(blue line) and BLT l /BLT2 +/+ mice (green line) demonstrated no detectable expression
of BLTl on T cells in any sample tested.
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Figure 20: BLT I is Expressed on CD8+ Effector, but not on Central Memory T cells.
CD8+ T cells cultures were prepared and shipped to our laboratory. CD8+ effector and
central memory T cells were stained with unconjugated 3D7 and either CD8-PE or CD62L-PE. Both populations are CD8+, but effector T cells are CD62L low and central
memory T cells are CD62L high. CD8 or CD62L staining are shown on the y-axis and
3D7 staining is shown on the x-axis. CD8+ efTector T cells demonstrate positive staining
for BLT 1, but not CD8+ central memory T cells.
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Figure 21: Dexamethasone Up-regulates BLT1 on T Effector but not T Central
Memory Cells. (a) surface expression ofBLTl on CD8+ central memory T cells (T ' M),
DEX-treated TCM, CD8+ effector T cells (TEFF) and BLTl -deficient DEX-treated T Fr
cells. DEX (100nM) was added in culture media during differentiation of T EFF, T M or
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The data shown a1'
representative of three independent experiments.

55

DISCUSSION

This section describes the generation and characterization of monoclonal
antibodies against both human and murine BLT1. Membrane proteins in general and
GPCRs in particular are known to be difficult immunogens for making monoclonal
antibodies. Use of knock out mice for generating high affinity antibodies to membrane
proteins such as L-selectin was highly successful (74). The general presumption being
that in knock-out animals the protein becomes non-self and therefore, immunogenic. The
immunization scheme of using 300.19 cells to express the protein of interest and the use
of BLT1-/- mice worked well to produce three sets of antibodies: those to HA-tag,
mBL T1 and hBLT1. Though we intended to produce antibodies that were cross-reactive
between human and murine BLT1, the resulting antibodies were found to be specific for
the immunized form of BLT1. Thus, despite the two proteins being highly homologous,
we generated antibodies specific to the unique regions of the receptors. Interestingly,
while the antibodies did not cross-react, both the human and murine BLTI antibodies
were specific for the ECL2 of the respective form of BLTI. This result may be placed in
the context that ECL2 is the largest of the extra cellular loops and therefore likely to have
contributed most epitopes. The fact that nearly 30 different antibodies for human BLTI
as well as the 8 antibodies for murine BLTl were all reactive against the ECL2 region
suggests that this region is probably immuno-dominant. In this context, it is interesting to
note that the most diverse region between the human and the murine BLT1 is ECL2.
While the mBLT1 and hBLT1 display ~79% homology the ECL2 region as shown below
is only 41.7% identical with only 10 identical residues out of24.
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hBLT1-AYRTVVPWKTNMSLCFPRYPSEGH

... .. ..
..

mBLT1-VYRTVK-WNNRTLICAPNYPNKEH

This result raises the question whether all of these antibodies may be against a
single epitope and originated from the same clone. However, it was found that antibodies
of the classes IgG 1, IgG2a and IgG2b subtype were found in the analysis of
representative antibodies (data not shown).

This demonstrates that these antibodies

originated from separate and distinct plasma cells. However, we could not reach firm
conclusions about the specific epitopes on murine and human BLTI recognized by our
panel of monoclonal antibodies. Further studies with additional chimeras in ECL2 region
and peptides corresponding to this region of mBLTI and hBLTI will delineate the
binding sites for all of the antibodies described here.
As all the hBLTIantibodies were identified by screening with HA-tagged hBLTI
expressing 300.l9 cells they were further tested and were reactive against RFP-fused
hBL TI. Moreover, they also recognized hBL TI expressed in a rat basophilic leukemia
(RBL) cell line suggesting that there are no cell type-dependent differences in epitope
recognition for exogenously expressed BLTI. To examine the expression of BLTI in
primary cells we stained human neutrophils and observed positive staining with most
antibodies. However, as described in Table 1 not all hBL TI antibodies were reactive
against human neutrophils. Since both primary and transfected cells were stained on the
same day it is not clear why some of these antibodies did not react with human
neutrophils. Since we used murine cells expressing the human BLTI for immunization,
it was possible species specific differences in glycosylation status might have contributed
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to differences in the reactivity of human neutrophils and transfected cells. However,
when mutants of BLTl that are defective in glycosylation were tested, all antibodies
reacted equally well indicating no effect of glycosylation status in BL Tl epitope
recognition.

Another possible explanation for the observed result is potential

polymorphisms in BL Tl gene; however this remains to be explored further.
A monoclonal antibody for hBLTl has been generated and used to show the
expression ofBLTl in monocytes and granulocytes from human peripheral blood by flow
cytometry (72). Minor subpopulations of CD19 and CD22 positive B cells and CD8
positive cells showed some BL Tl staining. In their studies, binding of antibodies to
BLTI was not blocked by adding synthetic peptides representing the extracellular loops
of BLTI suggesting that the epitopes may have been conformation-dependant. In
contrast, our use of chimeric receptors allowed mapping of the antibody binding site to
the ECL2. Since the antibodies described by Sabirsh et al also displayed species specific
reactivity, they might be binding to the similar sites in ECL2. Both antibodies were
found to block the function of the receptors as determined by increase in EC50 for
calcium, chemotaxis and MAP kinase activation (73). In preliminary experiments with
partially purified 6H12 antibody, we observed

~50%

inhibition of dose dependent

calcium mobilization. Recent studies from our laboratory showed that ECL2 is a critical
region for LTB4 binding in BLTI (12). Thus, the current demonstration that ECL2 is also
the binding site for BLTI antibodies offers an explanation for their functional blocking
capacity. Their potential use in the clinic, however, requires further in vitro and in vivo
characterization.
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Because our intent was to generate antibodies against both murine and human
BLTl, we initiated experiments to produce murine BLTl antibodies. The anti mBLTl
antibodies would be extremely useful in characterizing different knock-out and transgenic
animals developed in our laboratory as well as to address specific expression patterns and
regulation of BLTl in murine primary cells. As described in Results, we were quite
successful and generated eight independent monoclonal antibodies for mBL Tl. LTB4
responsive receptors have been demonstrated by function in multiple cell types of mice
and these antibodies have allowed us to begin probing these cells for expression. In
humans and in mice, neutrophils have been shown to be a key BLTl expressing cell. The
results presented here confirm that neutrophils are indeed the highest BLTl expressing
primary immune cells. Moreover, as might be expected the BLTl-/- mice did not show
any detectable expression of BL Tl. But more importantly, the new mBLTl antibodies
have allowed analysis of BLTl expression in BLT2-/- mice. Since both BLTl and BLT2
are closely linked in the genome and separated only by

~4.0

kb of intergenic region, the

influence of disrupting one gene on the expression of the other could be quite significant.
In this context, the data presented here shows that both in neutrophils and in eosinophils
the BLTl expression is similar to WT mice in BLT2-/- mice. This observation is
particularly relevant to the studies reported in Chapter III.
Analysis of BLTl expression in cells isolated from different tissues revealed
interesting patterns. Neutrophils and eosinophils showed high levels of expression when
analyzed from different tissues such as bone marrow, blood, lymph nodes and spleen. In
contrast, the expression of BLTl in macrophages showed significant variation based on
the tissue from which they were isolated. This may be related to maturation status of
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macrophages. Macrophages with high CD 11 b and CD 16 expression showed significant
BL Tl expression, whereas macro phages with low CD 11 b and CD 16 showed complete
lack of BLTI expression. In addition, macrophages from bone marrow displayed higher
levels of BLTI expression relative to blood monocytes. Previous studies from our and
other laboratories have shown functional expression of BLTI in murine and human
monocyte/macrophages. However, the current results suggest a potential for tissue and
maturation stage-dependent regulation of BLTI in macrophages.

Since macrophages

express high levels ofBLTl in the bone marrow, low levels ofLTB 4produced from bone
marrow-derived leukocytes might act as a retention signal for these cells. We propose
under conditions of inflammation, the balance shifts to increased tissue levels of LTB4
and as a consequence higher systemic levels of LTB4. Indeed, increased tissue and
systemic levels of LTB4 were reported in diverse inflammatory diseases including
atherosclerosis and arthritis. Increased levels of LTB4 have been observed in the blood
and synovial fluids of patients with rheumatoid arthritis (76, 77). This could then serve as
mechanism for rapid mobilization of inflammatory cells to the site of inflammation. The
decrease in BLTI levels in peripheral tissues could be related to the receptor activation
and down regulation due to increased LTB4 levels.
Although we did not detect any BLTI staining

III

our analysis of T or B

lymphocytes in peripheral blood or lymph nodes, several laboratories have demonstrated
functional expression on effector T cells. In previous studies expression of BLTI was
observed on activated T cells and the T cells we studied were resting and unactivated
which explains their lack of BL Tl expression. When effector and central memory CD8+
T cells were tested for expression of BL Tl, effector cells showed positive staining, while

60

central memory cells were completely negative. This is in line with the prevlOUS
functional data reported by Ott et al. (78) and later by Miyahara et al. (50) who showed
that BL T1 expression on CD8+ T cells is critical in murine models of airway hyperresponsiveness. More recently, using the biotinylated-3D7 antibody described in this
thesis, Ohno in Dr. Gelfand's laboratory identified that dexamethasone up regulates
BLT1 expression in effector memory CD8+ T cells (unpublished data). A certain
percentage of asthma patients treated with corticosteroids are insensitive to the drugs and
in some cases might exasperate the disease. The dramatic increase in the expression and
function of BL T1 by dexamethasone offers a potential explanation for steroid resistance
in asthma.
A large number of diseases have been associated with LTB4 and many would
likely be benefited by an antibody which blocks BLT1 function. That is an ultimate goal
of this research. What both the hBL T1 and mBL T1 antibodies allow for at this point is
the characterization of BL T1 in disease scenarios and in pre-clinical mouse models of
disease. For example, the mBLT1 antibodies will allow us to determine which cells
differentially express BLT1 during the development of different diseases given the ease
of being able to follow disease progression in mouse models.

The current studies

confirmed that neutrophils, eosinophils and macrophages express BLT1. Beyond that,
differential regulation of BLT1 in macrophages was identified.

In addition, steroid

induced up-regulation of BLT1 levels in T cells was demonstrated. Thus, the studies
presented are just a beginning of what could become an important area of study. This
understanding might allow us to proceed towards treating human disease.
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CHAPTER III

NON-REDUNDANT AND CRITICAL ROLES FOR
LEUKOTRIENE B4 RECEPTORS BL Tl AND BL T2 IN
MOUSE MODELS OF INFLAMMATORY ARTHRITIS

INTRODUCTION
Inflammation

The role of inflammation in disease processes of humans has become an
important topic recently even prompting a cover story on TIME magazine.

Many

diseases which had been simply associated with genetics have recently been intimately
associated with inflammation.

Atherosclerosis is one such case where it had been

thought that the disease was caused by faulty regulation of lipid metabolism, but is now
known to be largely due to chronic inflammation.

Inflammation was historically

described by the Latin words calor, dolor, rubor and tumor which mean heat, pain,
redness and swelling. Inflammation brings about these results by the action of cytokines,
chemokines and other mediators with their effects on leukocytes and the vasculature (79).
These mediators cause vasodialation, which causes the redness, heat and swelling and
brings in inflammatory cells, which by their actions cause the pain. In the initial stages
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of inflammation, neutrophils are the main cell type present followed by macrophages.
These two types of immune cells form the first line of defense in infection. Either
through additional cytokine and chemokine production, or through antigen presentation
by dendritic cells, the adaptive immune system becomes involved at later stages and
enables the immune system to be more focused in its attack.

These cells can once again

cause the recruitment of neutrophils and macrophages and in the case of acute infection
cause the clearance of the infectious agent and resolve the inflammation. In chronic
infections, the inflammation is ongoing and is not cleared. Chronic infections have been
linked to a number of auto-immune diseases (80-84). There are several mechanisms by
which this is thought to occur including molecular mimicry by the infectious agent (82).
A brief overview of what auto-immune disease is and what connections have been made
follows.
Auto-immune diseases are conditions where an individual's immune system
causes damage to the individual chronically.

Examples of auto-immune disease are

multiple sclerosis, systemic lupus erythematosus, myasthenia gravis and rheumatoid
arthritis. In multiple sclerosis, the body attacks the myelin sheath around nerves which
disrupts normal nerve function (85). In lupus, auto-antibodies are made against common
molecules such as double stranded DNA, nucleus or phospholipids and leads to a
multitude of problems in the joints, skin, kidneys, heart, lungs, blood or brain (86). Many
viruses have been associated with multiple sclerosis including Epstein-Barr virus (EBV)
(81, 83). EBV is also thought to lead to the development of systemic lupus erythematosus
due to EBNA-l of the virus having cross-reactivity with certain lupus auto-antigens (80,

82).
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Rheumatoid Arthritis

Rheumatoid arthritis is the emphasis in this thesis. Rheumatoid arthritis (RA)
affects 2.1 million Americans, which is 1% of the population. In RA, multiple joints are
usually inflamed in a symmetrical pattern and usually involve the small joints of the
hands or feet (87). Rarely, rheumatoid arthritis can even affect the joint that is responsible
for the tightening of the vocal cords to change the tone of the voice, the cricoarytenoid
joint (88). Though RA is a disease of mostly the joints, it does affect other parts of the
body. RA can cause Sjogren's syndrome, which is characterized by inflammation that
affects the glands of the mouth and eyes making them particularly dry (89). Pleuritis, or
inflammation of the lung, also occurs in RA patients, which causes tightness of the chest
and trouble breathing (90). Rheumatoid nodules occur under the skin around the elbows
and fingers (89). Other secondary effects of RA are pericarditis, anemia, decrease in
white blood cells due to enlarged spleen, and vasculitis. The main presentation of RA is
in the joints, however.

RA demonstrates alternating periods of flares and remission. Flares can present
as fatigue, lack of appetite, low grade fever, stiffness, and muscle and joint aches or can
cause red, swollen, painful and tender joints due to excessive synovial fluid production
and, of course, intense inflammation.

Remissions can occur naturally or through

interventions. They can last a few weeks or for years. During remissions, individuals
with RA can live a normal and healthy life.

What controls this cycle of flare and

remission is unknown, but drugs have been developed that allow remission periods to be
more frequent and to last for a greater length of time.
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Rheumatoid arthritis (RA) has had links to several infectious agents over the years
including Chlamydia pneumoniae (91), periodontal flora (84) and EBV (92). Indeed, one
of the models that will be discussed below absolutely requires the presence of a bacterial
stimulus (mycobacteria) for the model to work properly.

Absence or a lower

concentration of the mycobacteria causes the immunization protocol to be ineffective
(93). However, a definite connection between an infectious agent and RA has not been
proven.

Activation of synovial fibroblasts has been linked to infectious agents through
Toll Like Receptors (TLRs). The activated synovial fibroblasts produce proinflammatory cytokines, chemokines and matrix degrading enzymes (94). TLRs have
been recently demonstrated to be involved in the initial stage of synovial activation (95).
Microbial products or even RNA from necrotic cells within the synovium (96) cause
activation of the synovial fibroblasts and subsequent release of pro-inflammatory
cytokines and chemokines (97). Another possible initiation step involves the formation of
immune complexes resulting from auto-antibody production. Immune complexes have
been demonstrated to induce the production of leukotrienes by mast cells (98). This
production was absolutely necessary in an immune complex-induced peritonitis model in
mice. Recently, a pathway of joint inflammation involving the production of LTB4 by
mast cells was demonstrated. The mast cell generated LTB4 activates macrophages
leading to the production of TNF a (99). TNF a induces further production of LTB4 by
mast cells, which generates an amplification loop for the production of LTB4 and
persistent inflammation in the synovium.
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Many mechanisms are potentially involved in the resolution of inflammation.
One of these are the switch from S-LO and COX enzymes to IS-LO in leukocytes.
Where leukotrienes and prostaglandins are pro-inflammatory, the IS-LO products called
lipoxins are anti-inflammatory. In murine air pouch model was used to demonstrate the
temporal manner in which this transition occurs. Injection of sterile air on days 3 and 6
led to a significant production of prostaglandin E2 (PGE2), little LTB4 production and few
PMN s. When TNF a was administered, a large increase in LTB4 was demonstrated that
reached a maximum at I hour and preceded a large influx of PMN s that reached a
maximum at 2.5 hours. The maximum amount of PGE2 was seen at this time point as
well. A large increase in lipoxin A4 was seen by 4 hours and remained elevated while the
number ofPMNs and level ofPGE2 was reduced (100). Lipoxins have been demonstrated
to retard the entry of new neutrophils to the site (101), reduce vascular permeability (102)
and stimulate macrophages to phagocytose apoptotic neutrophils (103).
Another set of molecules that down-regulate inflammation are the resolvins.
Resolvins are derivatives of eicosapentaenoic acid have also been demonstrated in the air
pouch model to inhibit leukocyte trafficking to the air pouch (104). These molecules act
directly on leukocytes and have even been demonstrated recently to bind to BL TI
specifically to down-regulate its pro-inflammatory effects (105). As stated earlier, downstream effects ofLTB4-BLTI interaction are at least in part mediated through NFKB. It
was demonstrated that resolvin El dampens NFKB signaling upon interaction with its
receptors, ChemR23 (104), which again illustrates the importance ofBLTl in
inflammation.
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Treatment of RA

There is a long list of treatments for RA. General anti-inflammatory drugs such
as aspirin are used quite often, but more specific therapies have emerged such as antiTNFa treatment that has greatly advanced the treatment of RA.

Non-steroidal anti-

inflammatory drugs (NSAIDs) and corticosteroids are what are commonly referred to as
the first line drugs (106).

Some examples of NSAIDs are acetylsalicylate (aspirin),

naproxen, ibuprofen, and etodolac. NSAIDs are drugs that are used to reduce tissue
inflammation, pain and swelling. Aspirin has been used for centuries for headache and
other aches and pains.

In higher doses than for headache, it has been shown to be

effective in treating RA (107). In these high doses, NSAIDs have side-effects which
include stomach upset, abdominal pain, ulcers, and even gastrointestinal bleeding. Other
potential side effects may include damage to the liver and kidneys, ringing in the ears
(tinnitus), fluid retention and high blood pressure. To minimize the gastro-intestinal side
effects, NSAIDs should be taken with food and typically antacids and proton-pump
inhibitors are used. Aspirin is a COX-I inhibitor. COX-I and COX-2 both are enzymes
that produce pro-inflammatory prostaglandins from arachidonic acid. In an attempt to
block prostaglandin synthesis without the gastro-intestinal side-effects, COX-2 inhibitors
were developed. These compounds will be discussed further below.

Corticosteroids are the other first line treatment which can be taken orally or
directly injected into the joint (108, 109). Examples of corticosteroids are prednisone and
methylprednisolone. Corticosteroids are more effective in reducing inflammation than
NSAIDs and are better at increasing joint mobility. They are typically used for short
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periods during flares or when NSAIDs are not effective. Corticosteroids are used for
short periods due to side effects which include diabetes, weight gain, facial puffiness,
thinning of the skin and bone, easy bruising, cataracts, risk of infection, muscle wasting,
and destruction of large joints, such as the hips.

First line drugs are effective in blocking inflammation and pain, but are not
effective in stopping cartilage and bone destruction (110). For this, more specific drugs
are necessary which are termed disease-modifying anti-rheumatic drugs (DMARDs).
The first line drugs work quickly, but DMARDs can take months or even years to work
effectively. Due to the slow method of action and the fact that the DMARDs must be
tailored to specific patients, early treatment is critical in RA.

Some examples of

DMARDs are hydroxychloroquine, sulfasalazine, gold salts, D-penicillamine and
methotrexate. Sulfasalazine and methotrexate are commonly used because they have few
side effects. Methotrexate is the treatment of choice of the second line DMARDs (111).
Methotrexate is an immunosuppressive drug. Most immunosuppressive drugs are only
used in patients with severe disease or complications of RA. Methotrexate is used often
due to the ability to adjust dosing for the patient's specific needs.

Another type of second line drugs are biologic modifiers. One of the therapies
that is working well and gaining acceptance in the clinic is use of anti-TNF drugs such as
etanercept, infliximab, and adalimumab. These modifiers bind to TNF and block it from
interacting with its receptor and, thus, blocking the robust inflammation to which TNF
leads.

TNF blockers are generally taken in combination with methotrexate which

increases the efficacy of both treatments (112). Blocking of IL-1R with anakinra has

68

shown promise in the clinic (113).

It too is commonly used in combination with

methotrexate, but has not been as effective as the other biologic modifiers. Rituxan is an
antibody which binds to B cells and eliminates them. It has been effective in treating RA
in patients who do not respond to the anti-TNF therapies (114). Another treatment for
those who do not respond to anti-TNF therapies is abatacept, which blocks the activation
of T cells (115).

Treatments such as use of a Prosorba column are being studied currently (116).
The Prosorba column basically uses Protein A to bind antibody. The patient's blood is
pumped out into an apheresis machine to separate the plasma from the blood cells and the
plasma is passed over a Protein A column to remove the auto-antibodies present and then
pumped back into the patient. This procedure is not currently in use, but it is being
evaluated for effectiveness in the clinic.

Failure of COX-2 Inhibitors in Arthritis Therapy

One of the most effective RA treatments in recent years was the use of the COX-2
inhibitors. These include Celebex (Pfizer), Vioxx (Merck) and Bextra (Eli-Lilly). Again,
COX-2 inhibitors were investigated and used because COX-l inhibitors had gastrointestinal side effects. COX-2 inhibitors were found to have a decreased incidence of
these side effects; therefore, these compounds were given to patients for treatment of RA.
These patients were found to have an increased risk of myocardial infarction (117) and
the drugs were taken off the market quickly. RA has been shown to be linked to coronary
heart disease and cardiovascular mortality rate previously (118-122).

It has been

recognized for a half century that patients with RA die prematurely (123).

69

The

proportion of these deaths attributable to cardiovascular causes range from 39% to 50%
(124-126). One possibility is that RA leads to increases in pro-inflammatory molecules
in the periphery such as TNFa,

1L-1~

and 1L-6 (127).

Another possibility for the

increase is the treatment of RA itself. Corticosteroids have been shown to increase the
risk of atherosclerosis-associated cardiovascular events by five-fold in those taking high
doses of corticosteroids (128). A number of researchers are looking into this important
linkage between RA and heart disease. Another interesting connection to RA is a new
insight that, while cancer incidence is identical between normal individuals and RA
patients, cancer mortality is significantly higher in RA patients (129). Once again, the
mechanisms are not clear, but likely include altered states of the immune system, prior
treatments for RA and mental health.

Mechanisms of RA

Over and above the association of RA and heart disease already made, patients
treated with COX-2 inhibitors had an increase in cardiovascular events compared to
patients who did not take COX-2 inhibitors. It is obviously a complex situation involving
many parameters that must be studied further, but one simple explanation is that blocking
of COX-2 leads to increased production of leukotrienes. The COX enzymes compete
with 5-LO for arachidonic acid.

Blocking COX-2 could lead to increased levels of

arachidonic acid substrate for 5-LO to produce LTA4 and thereby, LTB 4. It has been
shown in animal models that mice deficient in the leukotriene pathway or treated with
pathway inhibitors are protected from developing atherosclerosis (43, 130). Specifically,
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part of my work has demonstrated that loss of BL Tl leads to a significant reduction in
plaque size in the ApoE deficient mouse model of atherosclerosis (35).

In both RA and atherosclerosis, inflammation is the culprit of the disease process.
In RA, inflammation leads to joint destruction which is characterized by inflammatory
influx into the joint synovium and into synovial tissue, synovial hyperplasia, and
abnormal cellular and humoral immune responses. Neutrophils, mast cells, T cells, B
cells, and macrophages all play an important role in disease progression and can be seen
in the joints of RA patients. The presence of all of these cells and the destructive results
listed are all due to the inflammatory process. As stated above, these cells are brought to
the site by cytokines, chemokines and other inflammatory mediators such as fMLP and
complement fragments. The complex interaction of these molecules and the cells that
produce them must be understood for treatment of the disease to progress.

Cytokines are small proteins that are released from cells, usually upon activation,
that modulate cells for particular tasks by binding specific receptors. Cytokines can work
in an autocrine manner where they act directly on the cell that produced them, a paracrine
manner where they act on cells that are close in proximity or in an endocrine manner
where they act on cells distant to the source of the production. They are grouped by
structure into the hematopoietins, interferons, immunoglobulin superfamily, TNF family
and others. Cytokines are categorized as inflammatory or anti-inflammatory, but this is
an over-simplification. Since many cytokines are released in most situations, the effect
they have on a cell depends on the other factors present in the system. Many cytokines
have been implicated in RA including IL-2, IL-6, IL-I2 and IL-I8 as positive regulators
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and IL-4 and IL-10 as negative regulators of disease (131-133). Most importantly, TNFa
and

IL-1~

have been shown to be intimately involved in RA (134) and blocking these

cytokines has been particularly effective in the clinic in treating RA (135, 136).
Chemokines are a sub-group of cytokines and include small proteins,
anaphylatoxins, bacterial proteins (fMLP), and lipids. Of the small protein chemokines,
there are many groups such as the ELR+ CXC, ELR- CXC, CC and CX3C chemokines.
These are grouped based on characteristic cysteines that these proteins contain which in
tum define the receptors that they bind. MCP-1 (137), CCL5 (138, 139), CXCL8 (140),
CXCL12 (141) and many other chemokines have been shown to be important for
recruitment of cells to the synovium in RA.

Quite potent lipid chemokines also exist

which include the prostaglandins, platelet-activating factor, and leukotrienes. These lipid
mediators are quickly produced upon cell stimulation because no transcription or
translation is needed to produce them. The enzymes needed to produce them are always
present and the substrate needed is found in the cell membrane.

Mouse Models of Arthritis
Models of arthritis have allowed for the elucidation of which cytokines,
chemokines and other molecules are important in RA. Commonly used models include
streptococcal cell wall-induced arthritis, collagen-induced arthritis and the KlBxN model.
The streptococcal cell wall-induced arthritis model is typically done in rats and involves
the i.p. injection of cell wall components of Group A streptococci.

This model is

preferential for females and leads to recurrent cycles of inflammation in the joints (142,
143). The pathology is similar to RA in the joints. Two very important models ofRA in
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mice are the collagen-induced arthritis and the KlBxN models of arthritis in mice.
Collagen-induced arthritis (CIA) has been the most widely used model of arthritis
initiated by intradermal immunization with type II collagen (144). The immunization
protocol varies due to a difference in susceptibility of the strains of mice, which is
thought to be due to MHC class linking.

DBA/l (H-2q) and BI0-RIll (H_2f) mice

develop disease following immunization with collagen in Complete Freund's Adjuvant
(CF A) for the first injection and using incomplete Freund's adjuvant (IF A) for the
booster two to three weeks later. CIA in mice has been shown to have several features in
common with human RA (145). In particular, the cytokine requirement and the effects of
cytokines on the development and progression of the disease appear similar to human
RA (146).

In this regard, TNF-a and IL-IP appear critical in the development and

progression ofRA (134). IL-2, IL-6, IL-12, and IL-18 act as positive modulators and IL4 and IL-I0 are negative modulators of the disease activity (131-133).
Two KlBxN mouse models of RA have attracted significant attention in recent
years (147, 148). The KlBxN model based on a T cell receptor (KRN) transgenic mouse
which produces a T cell repertoire that recognizes and makes auto antibodies to the
ubiquitous glycolytic enzyme, glucose-6-phosphate isomerase (GPI) and develops an
aggressive form of arthritis (149). In this case disease may also be transferred with serum
or purified antibodies. Disease development in this model is T and B cell independent
while neutrophils and mast cells are required for joint inflammation (150, 151). Within
CIA models and the KlBxN model, a prominent role for LTB4 in arthritis has been
demonstrated.
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Role of Leukotriene B4 Receptors in Arthritis

A role for LTB4 in rheumatoid arthritis was suggested by several observations
over the past two decades. Neutrophils from RA patients undergoing methotrexate
therapy displayed both acute and chronic suppression of LTB4 synthesis ex vivo (152).
This means that part of the efficacy of methotrexate therapy is likely due to this reduction
in LTB4 production in patients. In a recent study, a significant increase in the mRNA
levels of BLTI and BL T2 was seen in the joint tissues and cells from RA patients relative
to OA patients suggesting a role for these receptors in RA (153).
Targeted deletions in, or use of antagonists in, the leukotriene biosynthesis
pathway as well as deletions of the LTB4 receptors themselves have allowed for a fuller
understanding of the role LTB4 has in arthritis (Table 3). Much of the early data were
provided by antagonists.

In 1995, it was seen that the LTB4 receptor inhibitor CP-

105,696 was able to greatly reduce disease severity in an IL-l a accelerated CIA model
(154). Two more LTB4 receptor antagonists were used in the IL-la accelerated CIA
model with similar results (155). In an LPS accelerated CIA model, the LTA4H inhibitor
SA6541 was used and reduced the severity of disease in that study (156). Data utilizing
mice deficient in the leukotriene biosynthesis pathway in models of arthritis quickly
followed. FLAP knock-out mice were put through the IL-la accelerated CIA model and
found to have a 73% reduction in disease severity, which was associated with a 23%
decrease in disease incidence. FLAP heterozygous mice were shown to have a 37%
decrease in disease severity and a similar decrease in disease incidence as the FLAP
knock-out mice, suggesting that FLAP is a potential drug target (157). Though this
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pathway looked like a good target for arthritis treatment, attempts to use the antagonists
in clinical trials of arthritis often failed to improve RA.

Mouse Strain

Model of Arthritis

DBA/ILacJ

IL-l accelerated
CIA
IL-I Accelerated
CIA

DBA/I

DBAl1

LPS-accelerated
CIA
IL-18 accelerated
CIA

DBAl1

FLAP-IDBAIl
C57BI/6

lL-I Accelerated
CIA
KlBxN

BLT1-/- and
BLT1/BL T2-/C57BI/6

CIA

5-LO-/- and
LTA4H-/C57BI/6

KlBxN

BLT1-/C57BLl6

KlBxN

Experimental Results

References

Complete protection against disease development by
administration of BLTl antagonist CP-105,696
A 38% reduction III disease severity by
administration of BLTl antagonist LY29311lNa or
CGS25019C
Reduced severity of disease by administration
of LT ~H inhibitor SA6541
5-LO inhibitor MK-886 reduced the severity of
disease

(154)

Reduced incidence and severity of disease in FLAP1- mice relative to WT mice
by
Complete
protection
preventive
administration and reduced severity by
therapeutic treatment with 5-LO inhibitor L739,010 and with BLTl antagonist CP-I05,696
Complete protection from disease development
in BLT1-/- and BLT1/BL T2-/- mice. Similar
levels of auto antibody (anti-C II) production in
receptor deficient animals
Complete protection from disease development
in 5-LO-/- and LTA4H-/- mice. Adoptive transfer
of WT neutrophils is sufficient for disease
development in 5LO-/- mice
Complete protection from disease development
in BLT1-/- mice. Adoptive transfer of WT
neutrophils is sufficient for disease
development in BLT1-/- mice

(155)

(156)
(99)

(157)
(158)

(21 )

(151 )

(158)

Recent data has renewed interest in the LTB4 pathway as a target in arthritis.
Chen et al. showed that neither 5-LO nor LTA4 hydrolase knock-out mice develop
disease in the KlBxN model, while LTC4 synthase knock-out mice develop full disease.
Prophylactic treatment with a 5-LO antagonist also completely blocked disease from
occurring in wild-type mice. They went on to show in mast cell and neutrophil transfer
experiments that neutrophils are the primary source of LTB4 in KlBxN arthritis (151).
Using the BLTI knock-out animals, Luster's group showed a critical role for BLTI in
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KJBxN arthritis (158). BLTI-/- mice do not show any signs of arthritis.

Adoptive

transfer ofneutrophils from wild-type mice restored disease in these mice but most of the
recruited neutrophils in the synovium were BLTI negative suggesting that BLTI is
required only for initiation of joint inflammation but not maintenance. CP-I05,696 was
also shown to block disease occurrence in this model (158). Our studies with BLTI and
BL TlIBL T2 deficient mice in a CIA model also suggested a critical role for BL Tl in
arthritis. Both these mice showed similar levels of anti-collagen antibody levels
indicating normal immune response to collagen but complete absence of joint
inflammation (21).
These data demonstrate a need for the development of strategies to block the
actions of LTB4 in RA. In fact, a recent clinical trial was performed with BIIL-284
which is claimed to be an antagonist of both BLTI and BLT2. It was found in this study
that the antagonist did improve the disease in patients given the antagonist, but the results
were not significant compared to the placebo group (159). They concluded that LTB4
was not critical in the disease because it was only partially effective. A major problem
with this study is the fact that the specificity of this antagonist has not been fully
characterized. Only preliminary experiments have been done. Another problem is that
the dosage that was used in the clinical trial was lOX less than those necessary for
efficacy in mouse models.

Specific inhibitors for BL T2 and dual inhibitors for BLTI

and BLT2 are needed, especially since, as will be described below, BL T2 was identified
as a critical mediator of arthritis in the present study.
Our laboratory is currently involved in studies to produce these new antagonists.
Using molecular modeling, we have been able to demonstrate the amino acids necessary
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for the binding of LTB4 to BL T 1 and the residues which are required for activation of the
receptor (12). Mutation of the residues predicted to be involved in binding resulted in
loss of binding affinity demonstrating that predictions made from the modeling were
likely to be correct. This useful model of BLTI has allowed us to screen compound
libraries for novel antagonists of BL T1, which are yet to be tested (Basu et al.
unpublished). Modeling is currently underway for BL T2 and we will be able to screen
for novel antagonists targeting both BLTI and BLT2. In screening both receptors, we
hope to discover dual inhibitors which would potentially be useful in treating human
disease.
Since the loss of BL T 1 was enough for mice to be protected from arthritis
development, it was no surprise that BLTlIBLT2-/- mice did not develop disease (21).
This result suggests that BL T2 might not be important in RA. However, as shown below,
loss of BLT2 also protects mice from developing arthritis. Using the KlBxN model, we
showed that BLT2-/- mice developed very minimal signs of disease and using bone
marrow transfer experiments, the requirement for BL T2 expression by bone marrow
derived cells was shown. Moreover, using assays for BL Tl expression and function, it
was determined that BLTI is expressed and functional in BLT2-/- mice. Hence, both
BLTI and BLT2 may be required for the occurrence ofRA.
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MATERIALS AND METHODS
Mice
BLTl-l- mice on the Balb/c background were characterized and described in (59).
BLTl-l- mice on the C57B1I6 were characterized in (21). BLTl-l- were backcrossed 9
generations onto the DBAIl background and are described for the first time within this
thesis.

BLTlIBLT2-1- mice on the C57B1I6 background were characterized and

described in (21). BLT2 -1- were generated at the Duke University Transgenic Mouse
Core Facility and were subsequently backcrossed onto the C57Bl/6 background for 7
generations. BLT2-1- mice are described for the first time in this thesis. All studies and
procedures were approved by the Animal Care and Use Committee of University of
Louisville Research Resources Center.

RNA isolation and Reverse Transcription
Total RNA was isolated from bone marrow cells (BMC) using Trizol Reagent and
followed by mini RNeasy kit from Qiagen. Total RNA was treated with Turbo DNAase
from Ambion to remove the traces of genomic DNA contamination from RNA samples.
cDNA was synthesized from 250 ng of total RNA with random hexamer primers using
Taqman Reverse Transcription reagents (Applied Biosystems).

peR for mBL Tl and mBL T2
mBLTl, mBLT2 and

~-2

micro globulin (control gene) genes were PCR amplified

by HotStart Taq Polymerase (USB) using above synthesized cDNA (2 ilL per reaction) as
template with following primers in 20 ilL total reaction volume. The peR was also
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performed on the cDNA reaction mix that did not contain reverse transcriptase as a
negative control (data not shown).
mBLTl: Forward primer: 5' ATGGCTGCAAACACTACATCTCCT 3'
mBLTI: Reverse Primer: 5'-CACTGGCATACATGCTTATTCCAC-3'
mBLT2: Forward primer: 5' ATGTCTGTCTGCTACCGTCC 3'
mBLT2: Reverse Primer: 5' AGGTGCAGCA CAAGTGTGGC 3'
m~-2

micro globulin FP:

5' CATACGCCTG CAGAGTTAAG CA 3'

m~-2

microglobulin RP:

5' GATCACATGT CTCGATCCCA GTAG 3'

The PCR conditions used to amplify these products were as follows. The cDNA
(2 /-11) and forward and reverse primers (7.5 pmoles) were added to PCR tubes containing
0.2 mM dNTPs, 1.5 mM MgCh, 0.2 U of Hot start Taq DNA polymerase along with the
PCR buffer provided with enzyme IX concentration. The PCR conditions were: template
denaturation at 95°C for 4 min followed by 45 cycles at 95 °C for 30 sec (denaturation),
56°C (annealing) and 72 °C for 30 sec (extension). The reaction was continued for 5 min
to complete the extension. The expected sizes of the PCR products for mBLTI, mBLT2,
~-2

microglobulin were 319,191,73 bp respectively.

Calcium Flux
Calcium mobilization was monitored in Indo-I-loaded cells stimulated with
various concentrations of LTB 4 • Each experiment represents an analysis of 3 x 106 cells.
Neutrophils were elicited with zymosan for 4 hours and macrophages were elicited for 48
hours and were flushed from the peritoneum. They were then spun down, resuspended at
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2 X 106/mL in PBS + 1% BSA and loaded with 1.2 fll of pluronic acid (200 mg/ml in
Me2S0) and 1.5 fll of Indo-l (1 mM solution) and incubated for 30 min at 37°C. After
incubation, the cells were washed with PBS + 0.1 % BSA. The cells (2 x 106 cells/ml)
were resuspended in Hank's balanced salt solution containing 1 mM CaCb. The response
to various concentrations of ligand was recorded using a spectrofluorometer (F2500,
Hitachi, San Jose, CA).

CIA on the DBAII Background

Complete freund's adjuvant (CFA) was prepared by mixing 100 mg of heatkilled Mycobacterium tuberculosis (H37Ra; Difco Laboratories) in 20 ml of IF A (SigmaAldrich). An emulsion was formed by dissolving 2.0 mg/ml chick ClI (ClI; SigmaAldrich) overnight at 4°C in 10 mM acetic acid and combining it with an equal volume of
CFA. ClI solution and the emulsion with CFA were always freshly prepared. Mice were
anaesthetized with ketamine HClixylazine HCI (Sigma-Aldrich) and were injected i.d. at
the base of the tail with a total of 100 fll of emulsion containing 100 flg of ClI and 250 flg
of M tuberculosis. The same injection was repeated at day 21 in IF A.

KlBxN Arthritis

Serum from KlBxN arthritic mice was kindly donated by David Lee (Harvard
University). Sera were pooled to assure uniformity in the injections. 100 flL of serum
was injected i.p. on days 0 and 2 and mice were evaluated for clinical symptoms.
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Paw and Ankle Measurement and Clinical Scoring

Paw and ankle measurements were taken usmg a pocket thickness gauge
(Mitutoyo). All mice were examined every two to three days following appearance of
disease. Arthritis of each individual limb was graded using the following scoring system:
0, normal; 1, apparent swelling and redness limited to one digit; 2, swelling in more than
one digit; 3, severe redness and swelling of the entire paw; and 4, maximally inflamed
limb with involvement of paw and ankle joint. The maximum score per mouse was 16.
Mice were scored as arthritic if the clinical score was at least 2.

Bone Marrow Transfer

Recipient mice were irradiated with 900 rads to ablate all peripheral and bone
marrow cells. The following day, donor mice were sacrificed and the femurs and tibias
were removed and placed in RPMI medium. The bone marrow was flushed from the
bones with RPMI, washed, and resuspended in PBS. The bone marrow from one donor
mouse was used to reconstitute two recipient mice. Bone marrow was injected i.v. into
recipient mice and the mice were housed in sterile caging for at least four weeks. Mice
were allowed 8 weeks to engraft before they were taken for an experiment.

Histopathology

Upon termination of the experiment, mice were sacrificed and ankle joints were
removed from both hind legs. Ankles were placed in buffered 10% formalin for 16 hours
followed by transfer into 70% ethanol until samples were taken for sectioning. Ankles
were decalcified and paraffin embedded. Joint sections (5mm) were stained with H&E
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and examined for histological changes such as inflammation and bone destruction.
Representative pictures were taken using a Nikon Eclipse E400 microscope.
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RESULTS
Characterization of BLTl-/-, BL T2-/- and BL TIIBL T2-/- Mice

We have previously generated BLTI-/- and BLTlIBLT2-/- mice. In the current
studies we have generated BL T2-/- mice. The genomic locus spanning the BL Tl and
BL T2 genes and the strategy for making individual and double KO mice is shown in
Figure 22. Three primer PCR reactions were developed for determining the genotypes at
the BLTI and BLT2 loci. Routinely, mice were genotyped from DNA isolated from tail
snips using previously described procedures (21, 59). Figure 23a shows the genotyping
of all three BL T deficient mice used in the current studies. The same genomic DNA was
used in both PCR protocols to demonstrate clean recognition of the genotype of knockout mice. BLTlIBLT2+/+ PCR demonstrates only a wild-type band for both BLTI and
BLT2. BLTI-/- PCR demonstrates a wild-type band for BLT2 and a KO band for BLTI.
BLT2-/- PCR demonstrates a wild-type band for BLTI and a KO band for BLT2.
BLTlIBLT2-/- PCR demonstrates a KO band for both BLTI and BLT2. BLTl/BLT2 +/PCR demonstrates both the wild-type and KO bands for both BLTI and BLT2. BLTI +/PCR demonstrates a wild-type band for BLT2 and both a wild-type and KO band of
BLTI. BLT2 +/- PCR demonstrates a wild-type band for BLTI and both a wild-type and
KO band of BL T2.

Analysis of BL Tl and BL T2 Expression in Murine Bone Marrow

In Figure 23b, RT-PCR analysis was done using RNA isolated from the bone
marrow ofBLTlIBLT2+/+, BLTI-/-, BLT2-/- and BLTlIBLT2-/- mice. BLTl/BLT2+/+
bone marrow demonstrates expression of both BLTI and BLT2. BLTI-I- bone marrow
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shows no signal for BLTl, but demonstrates BLT2 signal. BLT2-/- bone marrow shows
no signal for BLT2, but demonstrates BLT2 signal. BLTIIBLT2-/- are negative for both
BL Tl and BLT2 signal.

BL Tl is Functional in BL T2-/- Mice
Since the experiments described in Chapter II showed some difference in BLTI
surface expression in BLT2-/- mice compared to wild-type mice, we determined the
functional expression of BLTI in BLT2-/- mice. For this, zymosan-elicited neutrophils
were tested for intracellular calcium release in response to LTB4. The expression of
BLTI on the elicited neutrophils is shown in Figure 24.

Any difference in BLTI

expression between BL TIIBLT2+/+ and BLT2-/- mice is not statistically significant.
The calcium flux response to LTB4 of wild-type neutrophils is shown in 25a. In 25b, the
calcium flux response of neutrophils from BLT2-/- mice to LTB4 is shown and is
virtually identical to the wild-type response if not slightly better. In 25c and 25d, the
calcium flux response of neutrophils from BLTI-/- and BLTl/BLT2-/- mIce,
respectively, is shown demonstrating no response at all.
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Mouse Genomic Locus
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Figure 22. Targeted Disruption of Leukotriene B4 Receptors. The strategy utilized to
produce knock-out an imals for the LTB4 receptors is shown. A diagram of the locus on
BL T I and BLT2 is shown at the top to demonstrate the regions deleted in each c nstmct.
The targeting construct for BLT2 is shown on the bottom. The construct contain the
same long arm fraglnent as the BLTlIBLI2 knock-out con tllct with a hort N-terminal
tretch of BLT2 followed by an E .. p and an omycin cassette. Following neomycin,
the remainder of the BL T2 sequence was kept due to the fact that the coding equence of
LT2 contains the promoter of BLI1, though no transcription should occur sinc the
neomycin cassette contains a stop sequence.
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Figure 23. Targeted Deletions of LTB4 Receptors. (aj GenQtyping: Genomic DNA
was isolated from mouse tails and peR was performed for both BLT! and BLT2 utilizing
eparate three primer reactions as described in methods (b) RT PCR: Total RNA was
isolated from Bone marrow cells (BMC) and cDNA was synthe ized from 250 ng of total
RNA with random hexamer primers. mBLT1, mBLT2 and ~ -2 microglobulin (control
gene) genes were peR amplified and the results hown. The product fo mBLTl,
mBLT2, ~ -2 micro globulin wer 319,191,73 bp respectively.
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Figure 24: BLTI Expression on Zymosan-elicited Neutrophils. Mice were injected
with 1 mL of Img/mL zymosan-a i.p. Following four hours incubation, the peritoneum
was washed with RPMI- 1640 containing 2% FBS and 0.2 mM EDT A. A sample was
taken and incubated with biotinylated-3D7 mouse monoclonal antibody and followed by
streptavidin-APC. The cells were analyzed on BD FACSCalibur with FL4 channel. The
mean fluorescence values of B TI KO (blue bar), BLT2 KO (red bar) and wild-type
(beige bar) neutrophils are shown (n=3).
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Figure 25: Calcium Flu of Zymosan-elicited Neutrophils. Mice were injected with 1
mL of Img/mL zymosan-a i.p. Following four hours incubation, the peritoneum was
washed with RPMI-1640 containing 2% FBS and 0.2 mM EDTA. The cell s were washed
with 1 X PBS + 1% BSA and processed for calcium flux. Concentrations of LTB4used
were 1 nM (green), 3 nM (purple), 10 nM (orange), 100 nM (brown), 300 11M (black) and
1000 nM (light blue). a) BLTlIBLT2 +/+ (wild type) b) BLT2-/- c) BLTI -ll d)
BLT J/BLT2-/- (double knock out)
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BLTI-/- Mice are Protected from CIA on the DBAll Background
Our laboratory has shown that BLTl is critical in the development of CIA on the
C57B1I6 background in mice (21). To test whether BLT1 was important in the more
commonly used model of CIA on the DBAll background, we bred our BLT1-/- mice
onto the DBAll background 9 generations. The mice paws were measured on day 0 of
the experiment for a baseline thickness and were measured on day 21 for a baseline
thickness of the ankle joint. Following the booster injection of collagen on day 21, the
mice were analyzed at least every 2-3 days for 3 parameters; clinical score, paw thickness
and ankle thickness. Heterozygous mice for BLT1 were bred to give BLT1 +/+, +/- and /- mice as littermates and were immunized for the development of CIA using protocols
described in Methods.

Figures 26 and 27 are representative of two independent

experiments. In both experiments, BLT1-/- mice were nearly completely protected from
clinical disease development, whereas BLT1 +/+ mice demonstrated severe arthritis
reaching a 100% incidence by day 58 of the experiment (26a). BLT1 +/+ mice started to
show an increase in ankle thickness (27b), paw thickness (27a) and clinical score (26b)
starting at day 24 and all these parameters continued to increase until the termination of
the experiment at day 70. BLT1-/- mice were protected from development of any clinical
signs of disease until day 49 when only 1 mouse showed clinical signs of disease (26a).
There is no drastic increase seen at any point in paw thickness (27a) or ankle thickness
(27b) in BLT1-/- mice. BLT1 +/- mice showed a definite delay in developing disease as
compared to BLT1 +/+ mice. BLT1 +/- mice did not show any signs of disease until day
34 and then the clinical score increased until the end of the experiment (26b). No drastic
increases in paw thickness (27a) or ankle thickness (27b) were seen until day 63 where
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both began to increase. Whereas +/+ mice reached 100% incidence on day 59, the +/mice only reached 100% incidence on the final day of the experiment (26a).

On day 70,

the difference between the clinical score of BLTI +/+ and BLTI +/- was significant (p<
0.05). Clinical scores were analyzed by non-parametric t-test in GraphPad Prism version
2.01.

Protection of Both BLTl-/- and BLT2-/- Mice from KlBxN Arthritis

Arthritis was induced in BLTlIBLT2+/+, BLTI-/- and BLT2-/- mice on the
C57Bl/6 background with 100 ilL of KlBxN arthritogenic serum injected i.p. on day 0
and day 2 and were followed every 1-2 days for signs of arthritis. This experiment is
representative of 3 experiments with BLTlIBLT2+/+ and BLT2-/- mice and 2
experiments with BL Tl-/- mice. The results of this experiment are shown in Figures 28
and 29. The clinical score is shown in 28b and demonstrates that BLTlIBLT2+/+ mice
get a very severe disease. BL T 1-/- mice had a slight clinical score from day 6 to 10, but
what little inflammation occurred resolved. BL T2-/- mice showed a similar fluctuation in
clinical score between day 6 to 10, but a minimal amount of inflammation remained
which is shown in 28b. In 28a, the incidence of arthritis is shown. BLTlIBLT2+/+ mice
reach 100% incidence by day 8, BLTI-/- mice have no incidence of disease and BLT2-/mice have a 20% incidence of disease starting at day 13. This incidence was due to one
BL T2-/- mouse getting arthritis in one paw as compared to BLTlIBLT2+/+ mice where
all five mice get disease in at least two paws. In 29a, it is shown that BLTIIBLT2+/+
mice began to have an increase in paw thickness at day 1 and the thickness continued to
increase until it reached a maximum at day 11. Neither the BLTI-/- nor the BLT2-/-
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mice showed any significant increase in paw thickness at any point in the experiment.
The ankle thickness shown in 29b had similar kinetics to the paw thickness with the
BL TIIBLT2+/+ mice beginning to increase at day 1 and reaching a maximum ankle
thickness at day 9, while neither the BLTI-/- mice nor BLT2-/- mice showed any
considerable increase. Representative histology is shown in Figure 30. A large influx of
inflammatory cells was seen in the bottom left ofthe BLTIIBLT2+/+ joint section at 40X
magnification.

When the section was viewed at 400X magnification, individual

inflammatory cells could be seen. Joint sections from BLTI-/- and BLT2-/- mice were
almost completely devoid of any signs of inflammation.
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Figure 26: Collagen Induced Arthritis (CIA) on DBA/1 Background: B Tl +1+
(blue), BLI I +1- (pink) and BLTI -1- (light blue) rnice on DBAIl back gro und were used
in the IA mouse model. These mice were observed every 2-3 da ys for vi ual ign of
arthritis. (a) Mice were considered arthritic when they demonstrated a stab le clinical
score of at least 2 (b) Clinical score was determined as described in Methods BLT t +1+
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Figure 27 : Change in Paw and Ankle Thickness in DBA/1 CIA. BLI ] +/+ (blue),
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Figure 30: Histology of KlBxN Ankle Joints. The ankle joints of B T1 /BL2 +/+,
BL Tl -/- and BLT2 -/- mice from mice subjected to induction of KlBxN arthritis were
sectioned and stained with Hand E. The images were obtained using Nikon Ec lip
400
microscope. Images at 40X magnification demonstrate infiltration of inflammatory cells
in BLTIIB T2 +/+ mice, but not in BLI I -/- and BLT2 -/- mice. Inflammatory cells
t 400X magnification, multiple
become more apparent at l OOX magnification.
individual inflammatory cells are seen in the BLTlIBLT2 +/+, while no inflammatory
cells are present in the BLT l -/- and BLT2 -/- pictmes.
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BLT2 is Required on Bone Marrow-Derived Cells for the Development of Arthritis
To determine whether the presence of BLT2 is required on bone marrow-derived
cells or other lineages, adoptive transfer experiments were undertaken. Recipient mice
were irradiated with 900 rads to completely eliminate all bone marrow and peripheral
blood leukocytes. The following day, bone marrow was isolated from donor animals and
injected i.v. into the recipient mice. Mice which are congenic for the SJL subtype of
CD45 antigen (CD45.1 or Ly5.l) were used in these experiments to distinguish
reconstituted leukocytes from any remaining recipient leukocytes (CD45.2 or Ly5.2).
Commercially available antibodies to these subtypes were used. The mice were tested for
their CD45 expression to determine how well the transplantation worked. The CD45
flow cytometry analysis is shown in Figure 31 for BLT2+/+ mice receiving BLT2+/+
bone marrow (31 a), BLT2-/- mice receiving BLT2+/+ bone marrow (31 b) and BLT2+/+
mice receiving BLT2-/- bone marrow (31 c) and demonstrate ~ 95-98% donor neutrophils
in the peripheral blood. Recipient mice were allowed to engraft for at least 8 weeks and
were then started on the KlBxN serum transfer arthritis protocol. In Figures 32 and 33,
the results of this experiment are shown.

These data are representative of three

independent experiments. The clinical scoring of these mice is shown in 32b and shows
BLT2+/+ mice receiving BLT2+/+ bone marrow (+/+D/+/+R (blue line)) and BLT2-/mice receiving BLT2+/+ bone marrow (+I+D/-/-R mice (purple line)) have an almost
identical course of disease reaching a maximum on day 9 while BLT2+/+ mice receiving
BLT2-/- bone marrow (-/-D/+/+R mice (orange line)) show very minimal signs of
disease. The incidence of disease is shown in 32a where it is seen that both +/+D/+/+R
and +/+D/-/-R mice reach 100% incidence on day 7 and -/-D/+/+R mice reach 20% on

97

the last day of the experiment again due to one mouse getting disease in one paw. In
+/+D/+/+R mice, an increase in paw thickness is seen by day 2 of the experiment and
reaches a maximum around day 8.

+/+D/-/-R mice show the same kinetics as the

BL T2+/+ recipients demonstrating an increase in paw thickness by day 2 and reaching a
maximum at day 7. -/-D/+/+R mice were completely protected from signs of increased
paw thickness more than some transient increases. A similar trend as 33a is seen in 33b
where both +/+D/+/+R and +/+D/-/-R show an increase in ankle thickness on day 2 and
reach a maximum around day 9 and -/-D/+/+R showing no drastic increase in ankle
thickness. Analysis of H & E staining of joint sections from these mice is shown in
Figure 34. BL T2+/+ mice reconstituted with BL T2+/+ bone marrow and BLT2-/- mice
reconstituted with BLT2+/+ bone marrow both show a drastic influx of inflammatory
cells at 40X magnification. At 400X magnification, inflammatory cells are easily seen in
these mice.

BLT2+/+ mice receiving BLT2-/- bone marrow show no signs of

inflammation at 40X magnification. The same region was taken at 400X magnification
as the mice reconstituted with BLT2+/+ showed no inflammatory cells.
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Figure 31: CD45 Expressjon Pattern of BLT2 +1+ and BLT2 -1- Reciprocal Bone
Marrow Transplants. Whole blood from mice was stained with D4S. I-PE and
D4S .2-FITC. D4S .2+ BLT2 +/+ and BLT2 -/- mice were reconstituted with CD4S. 1+
BLT2 +/+ bone marrow from CS7Bl/6 SJL congenic mic .
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(h) Clinical score was determined as described in Method .
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Figure 33: Change ill Paw and Ankle Thickness of Reciprocal Bone Marrow
Transplant Mice in K/BxN Arthritis. +/+ D/ +/+ R (blue), ~/- D/ +/+ R (orange) and
+/+ D/ -/- R (purple) mice were fo llowed every 1-2 days for increases in paw (a) and
ankle (b) thickness using a dial pocket thickness gauge.
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Figure 34: Histology of Ankle Joints for Reciprocal Bone Marrow Transplant Mice
in K/BxN Arthritis Experiments. The ankle joints of were section d and tained with H
and E. The images were obtained using Nikon Eclipse E400 microscope. Pictures at 40X
magnification demons trate infiltration of inflanunatory cells in BLT2 +/+ mice
reconstitut d with BLT2 +/+ bone marrow and BLT2 -/- mice reconstituted with BLT2
+/+ bon marrow, but not in BLT2 +/+ mice reconstituted with BLT2 -/- bone marrow.
Inflammatory cells become more apparent at lOOX magnification .
At 400X
magnification, multiple individual inflanunatory cells are seen in the LT2 +1+
reconstituted with BLT2 +/+ bone marrow and BLT2 -/- reconstituted with BLT2 +/
bone marrow pictures, while no inflammatory cells are present in the BLT2 +/+
recons tituted with BLT2 ./. bone marrow.
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BLTI and BLT2 are Non-Redundantly Required for Arthritis Development

Kim et al. previously demonstrated that BLTl-/- mice do not develop arthritis in
the KlBxN model, but develop disease if they are given BLTI+/+ neutrophils (158).
However, greater than 90% of the neutrophils in the synovium at the end of the
experiment were all BLTI-/- as determined by CD45 phenotyping. We believe BLTI-/neutrophils are likely recruited to the synovium via expression of BLT2. Given that we
have mice deficient in BLTI and BLT2, we have an excellent system to test this
hypothesis. If the preliminary stages of arthritis require BLT I expressing neutrophils and
the latter stages BLT2 expressing neutrophils, then reconstituting BL TlIBLT2-/- mice
with equal numbers ofBLTI-/- bone marrow cells (which should have functional BLT2)
and BLT2-/- bone marrow cells (which were shown above to express functional BLTI)
should lead to development of arthritis in these mice. If this hypothesis is wrong (if
simultaneous or sequential expression of BL TI and BL T2 is required), then no disease
will occur. The CD45 flow cytometry analysis for BLTIIBLT2-/- mice given
BLTlIBLT2+/+ bone marrow (35a) and BLTlIBLT2+/+ mice receiving a mixture of
BLTI-/- and BLT2-/- bone marrow (35b) and analysis of BLTl/BLT2+/+ mice given a
mixture ofBLTI-/- and BLT2-/- bone marrow with 3D7 and GR-I-PE (35c) is shown in
Figure 35. All the mice used in this experiment displayed ~ 95-98% donor neutrophils in
the peripheral blood with examples shown in 35a and 35b. Analysis of BLTlIBLT2+/+
which were reconstituted with a mixture of BLTI-/- and BLT2-/- bone marrow, showed
that ~ 50% of the peripheral neutrophils arose from BLT2-/- bone marrow while the other
50% was from BLTI-/- bone marrow in 35c.

Results shown in Figures 36 and 37 are

those generated from BLTlIBLT2+/+ or BLTIIBLT2-/- mice reconstituted with a
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mixture of 50% BLTI-/- and 50% BLT2-/- bone marrow or with BLTlIBLT2+/+ bone
marrow.

Controls are shown in Figures 36 and 37 where wild-type mice were

reconstituted with BLTI-/- or BLT2-/- bone marrow. Both BLTIIBLT2+/+ (blue line)
and BLTIIBLT2-/- mice (red line) reconstituted with BLTlIBLT2+/+ bone marrow
reached 100% incidence, though the BLTl/BLT2-/- recipients were delayed in reaching
100% by four days compared to the BLTlIBLT2+/+ recipients. This showed in the
clinical score in Figure 36b also, where BLTl/BLT2+/+ recipients reached a higher
maximum clinical score and reached it four days sooner than the BLTlIBLT2-/- recipient
mice. Though reconstitution with BLT2-/- bone marrow (orange line) or BLTI-/- bone
marrow (light blue line) led to no disease, there was a definite increase in clinical score in
both BLTlIBLT2+/+ (Pink line) and BLTIIBLT2-/- mice (green line) reconstituted with
50% BLTI-/- and 50% BLT2-/- bone marrow peaking at day 9 for the BLTl/BLT2+/+
recipients and day 10 for the BLTlIBLT2-/- recipients. The fact that BLTl/BLT2-/recipients showed an increase in clinical score compared to BLTlIBLT2+/+ recipients is
due in part because BL TIIBLT2-/- recipients had a 60% incidence of disease, while
BL TlIBL T2+/+ recipients had a 40% incidence of disease, as shown in Figure 36a. In
Figure 37a, it is shown once again that BLTIIBLT2+/+ mice reconstituted with
BLTl/BLT2+/+ bone marrow developed arthritis quickly with an increase in paw
thickness seen on day 2 and reaching a maximum at day 4.

BLTlIBLT2-/- mice

reconstituted with BLTlIBLT2+/+ bone marrow showed a similar maximum paw
thickness, though the kinetics were delayed such that these mice did not reach a
maximum until day 9.

BLTlIBLT2+/+ or BLTlIBLT2-/- mice reconstituted with a

mixture of BLTl-/- and BLT2-/- bone marrow did not show any drastic increase in paw
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thickness at any point.

In Figure 37b, BL TIIBL T2+/+ mIce reconstituted with

BLTIIBLT2+/+ bone marrow started to increase in ankle thickness by day 2 of the
experiment and reached a maximum thickness at day 9. Similar to the results seen with
the paw thickness measurement, BLTlIBLT2-/- reconstituted with BLTIIBLT2+/+ bone
marrow reached the same maximum level of ankle thickness, though the kinetics were
slightly delayed. A much more noticeable increase was seen in both BLTIIBLT2+/+ and
BL TlIBL T2-/- mice reconstituted with 50% BLTI-/- and 50% BLT2-/- bone marrow.
In Figures 36 and 37, wild-type mice reconstituted with BLTI-/- or BLT2-/- bone
marrow are shown. In Figure 36a, no disease incidence is shown in wild-type mice
reconstituted with either knockout bone marrow. In Figure 36b, a transient increase in
BL Tl-/- reconstituted mice is seen that quickly wanes, while no increase is seen in
BLT2-/- reconstituted mice. No significant increases in paw or ankle thickness were seen
in either set of mice in Figures 37a or b.
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Figure 35: Surface Receptor Characterization of Bone Marrow Transplant
Recipient Mice. Whole blood was stained with CD45.1-PE, and CD45.2-FITC.
CD45.2+ BLTlIBLT2 -/- mice were reconstituted with CD45.1 + BLTlIBLT2 +/+ bone
marrow. CD45.1+ BLTlIBLT2 +/+ mice were reconstituted with a 50% mixture of
CD45.2+ BLT2 -/- bone marrow and 50% of CD45.2+ BLTI -/- bone marrow. a)
CD45.2+ BLTlIBLT2 -/- mice reconstituted with CD45.1 + BLTlIBLT2 +/+ bone
marrow displayed > 98% of peripheral neutrophils were of donor origin . b) CD45.1 +
BLTlIBLT2 +/+ mice reconstituted with a 50% mixture of CD45.2+ BLT2 -/- bone
marrow and 50% of CD45.2+ BLT1 -/- bone marrow displayed > 98% peripheral
neutrophils were of donor origin.
c) Staining of the bone marrow cells with 3D7
(mBLT1 specific monoclonal antibody) and GR1 antibody.
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Figure 36: Mixed BL Tl -/- / BLT2 -/- Bone Marrow Transplants in KlBxN Arthritis.
BLTlIBLT2 +/+ recipient mice reconstituted with BLTlIBLT2 +/+ bone marrow (+/+ D/
+/+ R),BLTlIBLT2 +/+ recipient mice reconstituted with 50% BLTI -/- and 50% BLT2
-/- bone marrow (1 -/- / 2 -1- DI +1+ R), BLTlIBLT2 -/- recipient mice reconstituted with
BLTl/BLT2 +1+ bone marrow (+1+ DI 112 -1- R) and BLTl/BLT2 -/- recipient mice
reconstituted with 50% BLTI -1- and 50% BLT2 -/- bone marrow bone marrow (1 -1- / 2/- DI 112 -1- R were observed every 1-2 days for visual signs of arthritis. (aj The
incidence of clinical disease is shown demonstrating +1+ DI +1+ R (blue), +/+ D/ 112 -/R (red), 1 -1- 1 2 -1- D/ +/+ R (pink) and 1 -/- 1 2 -1- DI 112 -1- R (green) mice. . Mice
were considered to have disease when they reached a clinical score of 2. (bj Clinical
score was determined as described in Methods
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DISCUSSION

Previous data from our laboratory showed that mIce deficient

III

BLTI or

BL TlIBL T2 are completely protected from CIA on the C57Bl/6 background.
BL TlIBLT2 +/- mice displayed a delay in the onset and a lower incidence of disease, but
those mice that got disease had close to the same level of disease as wild-type mice. The
data presented in this thesis confirm all the previous findings of an essential role for
BLTI in murine arthritis. More importantly, they provide the first direct evidence for a
biological activity associated with BL T2 because targeted disruption of BLT2 led to a
complete protection against the development of serum transfer inflammatory arthritis.

BL Tl is Critical for Arthritis Development
A large body of data accumulated over the last decade has implicated LTB4 in
arthritis.

Despite persistent efforts from the pharmaceutical industry, no clear

therapeutics targeting this pathway are available for arthritis.

The current experiments

showed complete protection of BLTI-/- mice against development of arthritis the DBAIl
background for CIA. The BLTI +/- mice are delayed in incidence of disease compared
to wild-type littermates. They do reach 100% incidence by the end of the experiment, but
even at that time-point, the clinical score was significantly reduced compared to the wildtype mice (p< 0.05).

Measurement of the thickness of both the paw and ankle

demonstrated a direct measure of the inflammation seen in these mice and once again, a
delay in thickness is seen in the BLTI +/- mice in both the paw and ankle. In all these
parameters, BLTI-/- mice were greatly protected showing very minimal signs of disease
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in one mouse only. These data confirm that loss of BLTI protects mice from collagen
induced arthritis regardless of the background of the mice. It is also in agreement with
the BLTI antagonist study presented by Griffiths et al. in which they showed the
antagonist CP-I05,696 was almost completely effective in blocking clinical signs of
disease (154). When they gave the mice an injection of IL-l to accelerate the disease,
they saw a significant increase in disease severity in the mice treated with the lower
concentration of antagonist and a small increase in the animals treated with the higher
concentration of antagonist (157). Subsequent publications all used accelerated arthritis
models and only saw partial protection from arthritis.

When two other antagonists,

LY293111 Na and CGS25019C, were used in an accelerated model of CIA, the decrease
was not as significant as the previous study (only 38% reduced) (155). It is entirely
possible that the antagonists used in Kuwabara et al. were not as efficacious as CP105,696. However, the fact that CP-I05,696 was almost completely protective in those
experiments until IL-l was given to boost the mice demonstrates one simple point. BLTl
antagonism works well to block disease in non-accelerated CIA and IL-l acceleration
results in an inflammatory process that is not completely blocked by BLTI antagonism.
A straight-forward reason could be increased production of LTB4 in the synovium
beyond the point where CP-I05,696 or the other antagonists are effective. In fact, when
Kuwabara et al. tested the levels of LTB4 in the paws of these mice with and without the
IL-l acceleration, they saw a significant increase in LTB4 levels in the IL-l accelerated
mice over saline injected CIA mice at 6 hours (155). When they checked the LTB 4 leveis
at 24 hours, IL-l accelerated mice had 3X the levels of LTB4 in the paw than saline
injected CIA mice. It is logical to suggest that if the levels of LTB4 in a mouse triple,
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that the same amount of BL Tl antagonist would not be as effective. Another possible
explanation for reduced effectiveness of BLTI antagonists in IL-l accelerated CIA
models is that at high concentrations of LTB4, maintenance of arthritis in these mice
could be switched to BLT2 (see below). In this case, while a strong BLTI inhibitor
would work at initiation steps, once disease is initiated it might be more dependent on
BLT2. In the same study, they also found increased levels of prostaglandin E2 (PGE2) in
IL-l accelerated paws over saline controls. PGE2 is an inflammatory molecule and could
explain this increase in clinical disease also. In an IL-18 accelerated CIA protocol, a 5LO inhibitor was shown effective in lowering the severity of disease, while it did not
lower disease incidence by any significant level (99). Again in these experiments, if 5LO is activated by accelerated arthritis, then the inhibitor of 5-LO would not be nearly as
effective in blocking activity. When both the BLTI antagonists and 5-LO antagonists
were used in the KlBxN model which is not an accelerated disease, they were capable of
almost entirely eliminating signs of disease. Thus, previous findings of effective
inhibition of murine arthritis by BL Tl antagonists but clinical failure of the same
inhibitors as arthritis treatment will have to be reexamined in relapsing and remitting type
models of arthritis, similar to the EIA models. Unfortunately no such models are
currently available and further experimentation might have to rely on repeated
immunization or aggressive disease induction by cytokines like IL-l or use of repeated
induction of disease with the serum transfer.
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BL T2 is Critical for Serum Transfer Inflammatory Arthritis

The KlBxN model of arthritis has proven to be useful in determining which cells
are important in the effector phase of arthritis, by bypassing the steps of antigen
processing and display of auto-reactive peptides on dendritic cells and T and B cell
involvement. Having seen the result in CIA that BLTI -/- mice and BLTl/BLT2 -/- both
were protected completely from disease development, we were not certain BLT2 played
much of a role in arthritis. When we used BLT2 -/- mice in the KlBxN arthritis model,
however, we found that these mice were almost completely protected from disease
development. Very minimal signs of disease were noted with only one mouse showing
disease in one leg. This finding was also visualized in sectioning of the ankle joint,
where a large influx of inflammatory cells and bone destruction was seen in BLT2 +/+
sections, while little to no inflammation and bone destruction was seen in BLT2 -/sections. Our results also confirm the data of Kim et al. who saw a protection conferred
by the loss of BLTI (158). We used our BLTI -/- mice in this experiment and also did
not see any signs of disease in these mice either by macroscopic measures or in the
analysis of ankle sections. Thus, there is an apparent non-redundant requirement for both
BLTI and BL T2 in serum transfer-induced arthritis.
Since the expression of BL T2 in mice is not clearly established, it was difficult to
infer the cell type specificity of BLT2 expression required for induction of arthritis. To
more fully understand this requirement, we performed reciprocal bone marrow transfer
experiments between BLT2 +/+ and BLT2 -/- mice with a BLT2 +/+ mouse receiving
BLT2 +/+ bone marrow serving as a positive control.

Using this strategy, if the

expression of BLT2 is critical on bone marrow-derived cells, then recipient mice which
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receive BL T2 +/+ bone marrow will get disease whether they express BL T2 or not, thus
making BLT2 -/- mice capable of developing arthritis and BLT2 +/+ mice unable to get
arthritis. If the expression of BLT2 is required on non-bone marrow derived cells, then
expression of BL T2 on the donor bone marrow would have no effect and BLT2 +/+ mice
would get arthritis receiving BL T2 +/+ or BLT2 -/- bone marrow. To determine the
extent of bone marrow engrafiment, we utilized C57B1I6.SJL BLT2 +/+ mice which
carry the SJL CD45.1 marker, while our C57B1I6 BLT2-/- mice have the CD45.2 marker.
Utilizing this strategy, we found that only about 2-5% of circulating neutrophils were
derived from recipient bone marrow, which means 95-98% were produced from the
donor bone marrow. This experiment demonstrated an absolute requirement for BL T2 on
bone marrow-derived cells in arthritis induction. BL T2 +/+ and BLT2 -/- mice receiving
BLT2 +/+ bone marrow both developed arthritis at similar levels. In fact, the BLT2 -/recipients consistently demonstrated slightly higher disease parameters than the BLT2
+/+ recipients receiving BL T2+/+ marrow (positive control). BLT2 +/+ mice receiving
BLT2 -/- bone marrow were protected from development of arthritis indicating absolutely
no role for BL T2 on non-bone marrow-derived cells in arthritis development.
Histopathological examination revealed massive inflammatory cell influx in the BLT2-/mice receiving BL T2+/+ marrow. Since both of these mice express similar levels of
BLTI, it is clear that expression of BLTI alone in BLT2-/- mice is not sufficient for
arthritis induction.
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Induction of Arthritis in BL TIIBL T2-/- mice with bone marrow reconstitution from
both BL Tl -/- and BLT2 -/- deficient mice
We and others have shown that BLTI-/- mice do not develop arthritis in the
KlBxN model. The data from Kim et al suggest that this is at least in part due to the fact
that BL Tl must be present on neutrophils at early time-points, but is not necessary at
later time points (158). One could hypothesize that BL Tl is absolutely necessary on
neutrophils to initiate disease pathology.

Data from Chen et al. suggested that

neutrophils are the main source of LTB4 production in the synovium once they arrive
(151). This potentially leads to an accumulation of LTB4 to a level at which effectual
chemotaxis of neutrophils is not possible through BLTl. In this case, BL T2 could be the
chemotactic receptor to sense these higher concentrations of LTB4 at the site such that
BLTI is no longer necessary. Indeed, we showed above that BLT2-/- mice are protected
from development of arthritis. BLTlIBLT2 -/- mice should not develop KlBxN arthritis
given the results seen with the single knockout mice and the fact that BL Tl/BLT2 -/mice did not develop CIA (21). The question we sought to answer was if we reconstitute
a BLTl/BLT2 -/- mouse with both BLTI -/- BLT2 +/+ bone marrow and BLTI +/+
BLT2 -/- bone marrow, could the presence of BL Tl in a portion of neutrophils and BLT2
on the remainder of the neutrophils lead to disease development? In other words, does
expression of BLTI and BLT2 on separate cells induce arthritis in a mouse that lacks
both receptors?
To answer this question, we lethally irradiated both BLTlIBL T2 +/+ and
BLTl/BLT2 -/- mice and reconstituted them with either BL TIIBLT2 +/+ bone marrow or
an equal mixture ofBLTl -/- and BLT2 -1- bone marrow. After checking a blood sample
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for CD45 subtype expression, the mice with the best engraftment were taken through the
KlBxN model of arthritis. BL TlIBLT2 +/+ mice reconstituted with BLTlIBLT2 +/+
bone marrow demonstrated a rapid progression of disease as seen in the paw and ankle
thickness and clinical score. BLTlIBLT2 -/- mice reconstituted with BLTlIBLT2 +/+
bone marrow reached similar levels of disease as BLTl/BLT2 +/+ recipients, but the
kinetics of the disease process were slowed by a few days. We then demonstrated above
that BLT2 +/+ mice reconstituted with BLT2 -/- bone marrow did not develop arthritis. A
control group ofBL TlIBLT2 +/+ mice was reconstituted with BLTI -/- bone marrow and
these mice also did not develop any major signs of arthritis. Reconstituting BLTIIBLT2
+/+ and BLTl/BLT2 -/- mice with a mixture of both knock-out mouse bone marrow,
however, led to an increase in signs of arthritis over reconstitution with either single
knock-out bone marrow. Both BLTlIBLT2 +/+ and BLTlIBLT2 -/- recipients showed
an increase in ankle thickness, clinical score and incidence over time with BLTl/BLT2 /- recipients showing more of an increase in clinical score and incidence than that of
BL Tl/BLT2 +/+ recipients. Though the recipient mice did not get a wild-type level of
arthritis when reconstituted with a mixture of BL Tl -/- and BLT2 -/- bone marrow, there
is an undeniable increase in signs of arthritis. One possible explanation for this result is
that BL Tl and BLT2 have to be found on the same cell for full disease progression. Kim
et al. demonstrated a definite increase in disease parameters when BLTI -/- mice were
reconstituted with BLTI +/+ neutrophils, but the level of the increase in ankle thickness
and clinical score was about half of the level seen in BLTI +/+ mice (158). This is
similar to the level of disease that was seen in our BLTI -/- and BLT2 -/- bone marrow
mixture experiment. Since the coding regions of BLTI and BLT2 are so close on the
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chromosome and the promoter for BLTI is found in the coding region of BLT2, it is
possible that the two receptors could regulate one another and this is the reason BLTI
and BL T2 expression on separate cells is not enough to develop full disease, but still
produce enough inflammation for partial disease progression.
In summary, the results presented here suggest a novel and unexpected role for
the low affinity LTB4 receptor, BLT2, in arthritis. This result could explain, at least in
part, the failure of many clinical trials using specific antagonists for the high affinity
BLTI receptor. Targeting both LTB4 receptors with highly specific dual inhibitors might
offer an attractive treatment option for human RA.
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